<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004474.pub2" GROUP_ID="VASC" ID="833002052216254640" MERGED_FROM="" MODIFIED="2013-01-23 12:12:41 +0000" MODIFIED_BY="Fiona Taylor" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2&lt;/p&gt;&lt;p&gt;Old title: Tongxinluo capsule for unstable angina pectoris&lt;/p&gt;&lt;p&gt;26 Sept. 2005&lt;br&gt;Theresa: this version is amended according to the comments.&lt;/p&gt;&lt;p&gt;Taixiang&lt;/p&gt;" NOTES_MODIFIED="2013-01-23 11:52:22 +0000" NOTES_MODIFIED_BY="Fiona Taylor" REVIEW_NO="0214" REVMAN_SUB_VERSION="5.2.1 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2013-01-23 11:52:04 +0000" MODIFIED_BY="Fiona Taylor">
<TITLE>Tongxinluo (Tong xin luo or Tong-xin-luo) capsule for unstable angina pectoris</TITLE>
<CONTACT>
<PERSON ID="12346" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Taixiang</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Wu</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>txwutx@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL>http://www.chictr.org</URL>
<MOBILE_PHONE>+86 18980601801</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Chinese Clinical Trial Registry, Chinese Ethics Committee of Registering Clinical Trials</DEPARTMENT>
<ORGANISATION>West China Hospital, Sichuan University</ORGANISATION>
<ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chengdu</CITY>
<ZIP>610041</ZIP>
<REGION>Sichuan</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 28 8542 2081</PHONE_1>
<PHONE_2>+86 18980601801</PHONE_2>
<FAX_1>+86 28 8542 2253</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2013-01-23 11:51:05 +0000" MODIFIED_BY="Fiona Taylor">
<PERSON ID="12346" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Taixiang</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Wu</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>txwutx@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL>http://www.chictr.org</URL>
<MOBILE_PHONE>+86 18980601801</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Chinese Clinical Trial Registry, Chinese Ethics Committee of Registering Clinical Trials</DEPARTMENT>
<ORGANISATION>West China Hospital, Sichuan University</ORGANISATION>
<ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chengdu</CITY>
<ZIP>610041</ZIP>
<REGION>Sichuan</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 28 8542 2081</PHONE_1>
<PHONE_2>+86 18980601801</PHONE_2>
<FAX_1>+86 28 8542 2253</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="18963" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Roger</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Harrison</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>roger_harrison@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Epidemiology and Health Sciences</DEPARTMENT>
<ORGANISATION>University of Manchester</ORGANISATION>
<ADDRESS_1>Oxford Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M13 9PT</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 16 1275 1635</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19203" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Xiao</FIRST_NAME>
<MIDDLE_INITIALS>Y</MIDDLE_INITIALS>
<LAST_NAME>Chen</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>abilitywin@163.com</EMAIL_1>
<EMAIL_2>abilitywin@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE>+86 1371 839 6295</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>The General Hospital of the People's Liberation Army (PLAGH) (also Hospital 301)</ORGANISATION>
<ADDRESS_1>No. 28, Fuxing Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Beijing</CITY>
<ZIP>100853</ZIP>
<REGION>Beijing</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 10 6693 9115 ext:937086</PHONE_1>
<PHONE_2>+86 1371839 6295</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13911" ROLE="AUTHOR">
<PREFIX>Miss</PREFIX>
<FIRST_NAME>Juan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ni</LAST_NAME>
<SUFFIX/>
<POSITION>MSc Student</POSITION>
<EMAIL_1>nijuankiki@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Clinical Epidemiology</DEPARTMENT>
<ORGANISATION>West China Hospital, Sichuan University</ORGANISATION>
<ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chengdu</CITY>
<ZIP>610041</ZIP>
<REGION>Sichuan</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 28 8544 8570</PHONE_1>
<PHONE_2>+86 28 8542 2082</PHONE_2>
<FAX_1>+86 28 8554 2774</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12298" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Likun</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Zhou</LAST_NAME>
<SUFFIX/>
<POSITION>MSc student</POSITION>
<EMAIL_1>zhoubaling123@163.com</EMAIL_1>
<EMAIL_2>zhoubaling123@chinaren.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Clinical Epidemiology</DEPARTMENT>
<ORGANISATION>West China Hospital, Sichuan University</ORGANISATION>
<ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chengdu</CITY>
<ZIP>610041</ZIP>
<REGION>Sichuan</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 28 8542 2082</PHONE_1>
<PHONE_2/>
<FAX_1>+86 28 8554 2774</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12281" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Jieqi</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Qiao</LAST_NAME>
<SUFFIX/>
<POSITION>MSc student</POSITION>
<EMAIL_1>qiao-q@sina.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Clinical Epidemiology</DEPARTMENT>
<ORGANISATION>West China Hospital, Sichuan University</ORGANISATION>
<ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chengdu</CITY>
<ZIP>610041</ZIP>
<REGION>Sichuan</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 28 136 9348 6614</PHONE_1>
<PHONE_2/>
<FAX_1>+86 28 8554 2774</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13966" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Qin</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Wang</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>dr.qinwang@hotmail.com</EMAIL_1>
<EMAIL_2>wq3166@163.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Endocrinology</DEPARTMENT>
<ORGANISATION>West China Hospital, Sichuan University</ORGANISATION>
<ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chengdu</CITY>
<ZIP>610041</ZIP>
<REGION>Sichuan</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 13 8807 42865</PHONE_1>
<PHONE_2>+86 28 8542 2081</PHONE_2>
<FAX_1>+86 28 8554 2774</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="D37FC09A82E26AA20080535FC742FF64" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Jiafu</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Wei</LAST_NAME>
<SUFFIX/>
<POSITION>MSc Student</POSITION>
<EMAIL_1>weijiafu@hotmail.com</EMAIL_1>
<EMAIL_2>weijiafu@163.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Clinical Epidemiology</DEPARTMENT>
<ORGANISATION>West China Hospital, Sichuan University</ORGANISATION>
<ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chengdu</CITY>
<ZIP>610041</ZIP>
<REGION>Sichuan</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 28 8542 2081</PHONE_1>
<PHONE_2/>
<FAX_1>+86 28 8554 2774</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13838" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Xin</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Duan</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>dxbaal@hotmail.com</EMAIL_1>
<EMAIL_2>dxbaal@sina.com, Dxbaal@yahoo.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Orthopaedics</DEPARTMENT>
<ORGANISATION>The Second People's Hospital of Chengdu</ORGANISATION>
<ADDRESS_1>10 Qingyunnan Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chengdu</CITY>
<ZIP>610017</ZIP>
<REGION>Sichuan</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 138 8220 8059</PHONE_1>
<PHONE_2/>
<FAX_1>+86 28 8554 2774</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13974" ROLE="AUTHOR">
<PREFIX>Miss</PREFIX>
<FIRST_NAME>Jie</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Zheng</LAST_NAME>
<SUFFIX/>
<POSITION>MSc student</POSITION>
<EMAIL_1>shuiplpy@sina.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Clinical Epidemiology</DEPARTMENT>
<ORGANISATION>West China Hospital, Sichuan University</ORGANISATION>
<ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chengdu</CITY>
<ZIP>610041</ZIP>
<REGION>Sichuan</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 28 8542 2082</PHONE_1>
<PHONE_2/>
<FAX_1>+86 28 8554 2774</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-09-09 10:56:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NOTES="&lt;p&gt;Minor update: 16/02/07&lt;/p&gt;" NOTES_MODIFIED="2008-09-09 10:56:58 +0100" NOTES_MODIFIED_BY="Karen Hovhannisyan">
<UP_TO_DATE>
<DATE DAY="11" MONTH="8" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="11" MONTH="8" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="12" YEAR="2007"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2013-01-23 11:52:04 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Feb 2007 - minor amendment to author citation&lt;/p&gt;" NOTES_MODIFIED="2013-01-23 11:52:04 +0000" NOTES_MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2013-01-23 11:52:04 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="1" YEAR="2013"/>
<DESCRIPTION>
<P>Authors unable to update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-01-23 11:51:30 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-01-23 11:51:30 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="11" MONTH="8" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Chinese Cochrane Centre, West China Hospital of Sichuan University</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Chinese Medical Board of New York (CMB)</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Cochrane Heart Group</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-01-23 11:52:22 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>Tongxinluo (a traditional Chinese medicine) capsules may help patients suffering from unstable angina</TITLE>
<SUMMARY_BODY>
<P>Tongxinluo, in capsule form, is a traditional Chinese medicine which consists of herbs and insects. Traditionally it has been thought to have clinical benefits for patients with angina, including the reduction of the occurrence of acute myocardial infarction (AMI), and complications of some types of heart surgery. Some studies also suggest a possible benefit in reducing the frequency and severity of angina attacks and improving symptoms. However, none of these individual studies have been reviewed systematically.</P>
<P>The review authors systematically reviewed evidence from 18 randomised controlled trials for the benefit of tongxinluo with or without other treatments, including routine care or placebo, for patients with unstable angina. All the trials were conducted in China. The total number of participants was 1413, ranging in age from 25 to 88 years. Most studies randomised patients to receive tongxinluo with conventional medication or conventional medications alone. </P>
<P>There was some evidence from seven studies that tongxinluo improved the electrocardiogram (ECG) changes indicating ischaemia and reduced the number of people with no improvement or worsening of ECG (six studies). Some improvement in angina symptoms (10 studies) and reduced numbers of people showing no improvement or worsening of symptoms were apparent with tongxinluo. Tongxinluo appeared to be as effective as isosorbide mononitrate in three studies. A few cases of slight gastrointestinal discomfort were reported after giving tongxinluo in seven studies and three cases of breaking of tiny blood vessels under the skin (ecchymosis) in one study. </P>
<P>The evidence suggested possible benefits relating to a range of outcomes among patients with unstable angina but all the studies were of poor quality and neither blinding nor allocation concealment were used. This makes it impossible to reach firm conclusions about the benefit of this treatment. Large, high quality, randomised controlled trials are needed to confirm the possible benefit of tongxinluo for unstable angina and to suggest appropriate future use of this herbal medicine.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Tongxinluo capsule is a medicine consisting of traditional Chinese herbs and insects used for cardiovascular diseases in China and some other Asian countries. To date the evidence of its effect has not previously been subject to systematic review, making it difficult to derive robust conclusions about its actual benefits, and indeed, possible harms.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess systematically the effects of tongxinluo capsule in people with unstable angina pectoris.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library, Issue 4 2004, MEDLINE, EMBASE, Chinese Biomedical Database , China National Knowledge Infrastructure , Japana Centra Revuo Medicina (all 1995 to 2005). We also handsearched the relevant Chinese journals, checked with manufacturers and registers of ongoing studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised trials comparing either tongxinluo capsule only or standard treatment plus tongxinluo capsule with standard treatment or other anti-angina pectoris drugs, placebo or no intervention.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two authors identified relevant studies for the review independently and went on to abstract data, and assess trial quality. Authors of included studies were contacted to obtain further information as required.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>18 short term follow-up trials involving 1413 people were included. The studies did not provide strong support of a benefit of tongxinluo for reducing the combined outcome of acute myocardial infarction, angioplasty (PTCA) coronary artery bypass graft (CABG) and sudden death or all-cause mortality (RR 0.42, 95%CI 0.07 to 2.59, P=0.35; RR 0.33, 95%CI 0.01to 7.78, P=0.49, respectively). Tongxinluo reduced the frequency of acute angina attacks (WMD -1.20, 95%CI -1.38 to -1.02, P&lt;0.00001 and RR -2.36, 95%CI -2.53 to -2.18, P&lt;0.00001, respectively), improved ECG (RR 1.31, 95%CI 1.08 to 1.57, P=0.005) and angina symptoms (RR 1.21, 95% CI 1.06 to 1.40; P=0.007). </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Tongxinluo in combination with routine angina therapy appears to reduce the risk of subsequent AMI, PTCA or CABG, angina attacks and severity, as well as improving symptoms and ischaemic changes on the electrocardiogram (ECG). Due to the methodological limitations of the studies, the evidence is insufficient to make any conclusive recommendations about the use of this treatment for patients presenting with unstable angina. Large high quality randomised controlled trials are warranted.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>
<B>Description of the condition<BR/>
</B>Angina is a common presenting symptom (typically as chest pain) among patients with coronary artery disease (<LINK REF="REF-Braunwald-1989" TYPE="REFERENCE">Braunwald 1989</LINK>; <LINK REF="REF-Braunwald-1994" TYPE="REFERENCE">Braunwald 1994</LINK>). Myocardial ischaemia develops when coronary blood flow becomes inadequate to meet myocardial oxygen demand. Angina pectoris is the most common clinical manifestation of myocardial ischaemia and often occurs when the heart needs more blood. It may happen during exercise, strong emotions or extreme temperatures. Some people, such as those with a coronary artery spasm, may have angina when resting. Angina is a sign of increased risk of heart attack, cardiac arrest or sudden cardiac death (<LINK REF="REF-Braunwald-1989" TYPE="REFERENCE">Braunwald 1989</LINK>; <LINK REF="REF-Braunwald-1994" TYPE="REFERENCE">Braunwald 1994</LINK>). </P>
<P>Ischaemic heart disease is the most common cause of death in Western countries, where it accounts for almost 33% of overall mortality (<LINK REF="REF-Braunwald-1992" TYPE="REFERENCE">Braunwald 1992</LINK>). In recent years, there has been an increasing tendency for ischaemic heart disease incidence to rise in developing countries and this coincides with their economic development. For example in China, a study showed incidence of coronary heart disease might increase by 26.1% for male and 19.0% for female between 1998 to 2008 (<LINK REF="REF-Wu-2001b" TYPE="REFERENCE">Wu 2001b</LINK>).</P>
<P>
<B>
<I>Unstable angina</I>
</B>
<BR/>Unstable angina, together with ST-segment elevation and nonST-segment elevation myocardial infarction, is included as one of the events that are collectively known as acute coronary syndrome (<LINK REF="REF-ACC-2001" TYPE="REFERENCE">ACC 2001</LINK>; <LINK REF="REF-ICSI-2005a" TYPE="REFERENCE">ICSI 2005a</LINK>). Unstable angina is defined as angina that occurs at rest and is prolonged, usually lasting more than 20 minutes, or new onset angina of at least Canadian Cardiovascular Society (CCS) class III severity (<LINK REF="REF-CCS-1972" TYPE="REFERENCE">CCS 1972</LINK>), or recent acceleration of angina reflected by an increase in severity of at least 1 CCS class to at least CCS class III (<LINK REF="REF-ICSI-2005a" TYPE="REFERENCE">ICSI 2005a</LINK>). De novo effort angina, worsening effort angina, and spontaneous angina are frequently referred to as "unstable angina"(<LINK REF="REF-Braunwald-1989" TYPE="REFERENCE">Braunwald 1989</LINK>). Most people with angina can live for many years, but the risk of acute myocardial infarction (AMI) and sudden death is increased. This is particularly true for patients with unstable angina where the risk is much higher (<LINK REF="REF-KAU-1996" TYPE="REFERENCE">KAU 1996</LINK>).</P>
<P>In people with unstable angina, chest pain is unexpected and usually occurs while at rest. The discomfort may be more severe and prolonged than typical angina, or it may be the first time a person experiences angina. The most common cause is reduced blood flow to the heart muscle due to narrowing of the coronary arteries by atherosclerosis. An artery may be abnormally constricted or partially blocked by a blood clot. Inflammation, infection and other secondary causes can also lead to unstable angina (<LINK REF="REF-Braunwald-1994" TYPE="REFERENCE">Braunwald 1994</LINK>; <LINK REF="REF-KAU-1996" TYPE="REFERENCE">KAU 1996</LINK>).</P>
<P>Unstable angina should be treated as an emergency. People with new, worsening or persistent chest discomfort should be monitored carefully. They are at increased risk of acute myocardial infarction (heart attack) or severe cardiac arrhythmias. These can include ventricular tachycardia and fibrillation, or cardiac arrest leading to sudden death (<LINK REF="REF-Braunwald-1989" TYPE="REFERENCE">Braunwald 1989</LINK>; <LINK REF="REF-Braunwald-1994" TYPE="REFERENCE">Braunwald 1994</LINK>; <LINK REF="REF-ICSI-2005a" TYPE="REFERENCE">ICSI 2005a</LINK>; <LINK REF="REF-KAU-1996" TYPE="REFERENCE">KAU 1996</LINK>, ).</P>
<P>
<B>Description of the interventions<BR/>
</B>The main goals of treatment in patients with angina pectoris, including unstable angina, are relief of symptoms, slow ing down progression of the disease, and the reduction of future events, especially myocardial infarction and death (<LINK REF="REF-Braunwald-1994" TYPE="REFERENCE">Braunwald 1994</LINK>; <LINK REF="REF-ICSI-2005a" TYPE="REFERENCE">ICSI 2005a</LINK>; <LINK REF="REF-KAU-1996" TYPE="REFERENCE">KAU 1996</LINK>, ).</P>
<P>Sublingual nitroglycerin has been the mainstay of treatment for angina pectoris. This can be used both for acute relief of angina as well as prophylactically i.e. before activities that may precipitate angina. No evidence exists that long acting nitrates improve survival in patients with coronary artery disease (<LINK REF="REF-Braunwald-1994" TYPE="REFERENCE">Braunwald 1994</LINK>; <LINK REF="REF-ICSI-2005a" TYPE="REFERENCE">ICSI 2005a</LINK>; <LINK REF="REF-KAU-1996" TYPE="REFERENCE">KAU 1996</LINK>).</P>
<P>Beta-blockers are also used for symptomatic relief of angina and prevention of ischaemic events. These work by reducing myocardial oxygen demand by decreasing heart rate and myocardial contractility. It has been shown that beta-blockers reduce mortality and morbidity following acute myocardial infarction (<LINK REF="REF-Braunwald-1994" TYPE="REFERENCE">Braunwald 1994</LINK>; <LINK REF="REF-ICSI-2005a" TYPE="REFERENCE">ICSI 2005a</LINK>; <LINK REF="REF-KAU-1996" TYPE="REFERENCE">KAU 1996</LINK>).</P>
<P>Long-acting calcium channel blockers, which slow down heart rate, can be used to control anginal symptoms in patients with a contraindication to beta-blockers as well as those in whom symptomatic relief of angina cannot be achieved by the use of beta-blockers, nitrates or their combination. However short-acting dihydropyridine calcium channel blockers should be avoided because they have been shown to increase the risk of adverse cardiac events (<LINK REF="REF-Braunwald-1994" TYPE="REFERENCE">Braunwald 1994</LINK>; <LINK REF="REF-ICSI-2005a" TYPE="REFERENCE">ICSI 2005a</LINK>; <LINK REF="REF-KAU-1996" TYPE="REFERENCE">KAU 1996</LINK>).</P>
<P>Anginal symptoms in patients with Prinzmetal angina can be treated with calcium channel blockers with or without nitrates. In patients with syndrome X and hypertension, ACE inhibitors may normalise thallium perfusion defects and increase exercise capacity (<LINK REF="REF-Braunwald-1994" TYPE="REFERENCE">Braunwald 1994</LINK>; <LINK REF="REF-ICSI-2005a" TYPE="REFERENCE">ICSI 2005a</LINK>; <LINK REF="REF-KAU-1996" TYPE="REFERENCE">KAU 1996</LINK>).</P>
<P>
<B>How tongxinluo might work and why it is important to do this review<BR/>
</B>Chinese herbal medicine is part of Traditional Chinese Medicine (TCM), which is a 3000-year-old holistic system of medicine combining the use of medicinal herbs, acupuncture, food therapy, massage and therapeutic exercise for both the treatment and prevention of disease (<LINK REF="REF-Fulder-1996" TYPE="REFERENCE">Fulder 1996</LINK>). TCM has unique theories for concepts of aetiology and systems of diagnosis and treatment, which are vital to its practice. TCM drug treatment consists typically of complex prescriptions of a combination of several components. The combination, based on the Chinese diagnostic patterns (ie, inspection, listening, smelling, inquiry, and palpation), follows a completely different rationale than many western drug treatments (<LINK REF="REF-Liu-2000" TYPE="REFERENCE">Liu 2000</LINK>).</P>
<P>Tongxinluo capsule is a new drug, studied clinically since 1995, for cardio-cerebral vascular diseases. It is on the national essential drug list of China, and has the second-class award of the National Science and Technology Development of China, 2001(<LINK REF="REF-Anon-2002" TYPE="REFERENCE">Anon 2002</LINK>). The composition of tongxinluo capsule includes Radix ginseng (10%~20%), Scorpio (10%~20%), Hirudo (20%~30%), Eupolyphaga seu steleophage (10%~20%), Scolopendra (6%~15%), Periostracum cicadae (10%~20%, Radix paeoniae rubra (5%~15%), and Borneolum syntheticum (2%~10%) (<LINK REF="REF-Anon-2002" TYPE="REFERENCE">Anon 2002</LINK>; <LINK REF="REF-Liu-1997" TYPE="REFERENCE">Liu 1997</LINK>; <LINK REF="REF-Wu-1998" TYPE="REFERENCE">Wu 1998</LINK>; <LINK REF="REF-Wu-2001a" TYPE="REFERENCE">Wu 2001a</LINK>). These materials are ground to a fine powder and prepared as capsules (<LINK REF="REF-Wu-2001a" TYPE="REFERENCE">Wu 2001a</LINK>). The dose of tongxinluo in the treatment of cardio-cerebrovascular diseases is 1.14g to 1.52g in 3 to 4 capsules (0.38g in each capsule) and administered 3 to 4 times, a total dose of between 3.5g to 6.0g per day. Treatment is given as a four week course (<LINK REF="REF-Wu-2001a" TYPE="REFERENCE">Wu 2001a</LINK>). </P>
<P>Pharmacological studies show that <BR/>
</P>
<UL>
<LI>Radix ginseng strengthens cardiac contractility, increases cardiac output, has a cardiokinetic function (<LINK REF="REF-Jin-1983" TYPE="REFERENCE">Jin 1983</LINK>; <LINK REF="REF-Pei-1986" TYPE="REFERENCE">Pei 1986</LINK>), slows heart rate (<LINK REF="REF-Gu-1983" TYPE="REFERENCE">Gu 1983</LINK>; <LINK REF="REF-Pei-1986" TYPE="REFERENCE">Pei 1986</LINK>; <LINK REF="REF-Yuan-1983" TYPE="REFERENCE">Yuan 1983</LINK>), dilates blood vessels, is an anticoagulant and inhibits platelet adhesion reaction (<LINK REF="REF-Xu-1988a" TYPE="REFERENCE">Xu 1988a</LINK>). </LI>
<LI>Hirudo acts as an anticoagulant (<LINK REF="REF-Ou-1987" TYPE="REFERENCE">Ou 1987</LINK>) is thrombolytic, reduces viscosity of whole blood (<LINK REF="REF-Xu-1988b" TYPE="REFERENCE">Xu 1988b</LINK>), is anti-myocardial ischaemia (<LINK REF="REF-Li-1989" TYPE="REFERENCE">Li 1989</LINK>; <LINK REF="REF-Zhang-1978" TYPE="REFERENCE">Zhang 1978</LINK>; ), reduces cholesterol and is anti-atherosclerotic in action (<LINK REF="REF-Wu-1994" TYPE="REFERENCE">Wu 1994</LINK>). </LI>
<LI>Periostracum cicadae is anticonvulsive and significantly slows heart rate (<LINK REF="REF-Zheng-1998" TYPE="REFERENCE">Zheng 1998</LINK>). </LI>
<LI>Scolopendra extraction apparently strengthens cardiac contractility, decreases blood pressure, and increases blood vessel perfusion flow (<LINK REF="REF-Chen-1985" TYPE="REFERENCE">Chen 1985</LINK>). </LI>
<LI>Radix paeoniae rubra acts as a diuretic, has anticoagulant properties, can prevent thrombosis, and clearly inhibits the formation of platelet and fibrin thrombi (<LINK REF="REF-Deng-1991" TYPE="REFERENCE">Deng 1991</LINK>; <LINK REF="REF-Nu-1983" TYPE="REFERENCE">Nu 1983</LINK>). It can also apparently directly dilate the coronary artery, has strong anti myocardial ischaemia functions, changes the composition of lipoprotein, reduces calcium ion sediments on the arterious parietes and reduces atherosclerosis (<LINK REF="REF-Wang-1980" TYPE="REFERENCE">Wang 1980</LINK>; <LINK REF="REF-Zhang-1990" TYPE="REFERENCE">Zhang 1990</LINK>). </LI>
<LI>Eupolyphaga seu steleophage increases cardiac output and improves the tolerance of hypoxia (<LINK REF="REF-Nong-1989" TYPE="REFERENCE">Nong 1989</LINK>; <LINK REF="REF-Yang-1989" TYPE="REFERENCE">Yang 1989</LINK>). </LI>
<LI>Borneolum syntheticum is an analgesic and sedative (<LINK REF="REF-Wu-2001a" TYPE="REFERENCE">Wu 2001a</LINK>). </LI>
<LI>Scorpio is used in traditional Chinese medicine mainly for hypertension, apoplexy, arteriosclerosis, some nervous system diseases, various swellings and infections (<LINK REF="REF-Wang-1998" TYPE="REFERENCE">Wang 1998</LINK>). </LI>
</UL>
<P>These compositions and their pharmacological action are listed in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> with Latin and common names. </P>
<P>In experimental studies on animal models, tongxinluo improved myocardial ischaemia, prevented the occurrence of arrhythmia and hyperlipidaemia, increased coronary arterial blood flow, dilated the coronary vessels, improved myocardial blood supply and increased left ventricular work resulting in the enhancement and readjustment of the "pump" function of heart and improvement of the intravascular stasis condition of blood circulation (<LINK REF="REF-Liu-1997" TYPE="REFERENCE">Liu 1997</LINK>; <LINK REF="REF-Shang-1997" TYPE="REFERENCE">Shang 1997</LINK>). </P>
<P>Some randomised controlled trials report that tongxinluo can effectively relieve angina, improve electronic cardiography (ECG), reduce the frequency of acute attacks of angina and the use of nitroglycerine and improve vascular endothelium function of patients with unstable angina (<LINK REF="STD-Jia-1999" TYPE="STUDY">Jia 1999</LINK>; <LINK REF="STD-Su-2000" TYPE="STUDY">Su 2000</LINK>; <LINK REF="STD-Wang-2003a" TYPE="STUDY">Wang 2003a</LINK>; <LINK REF="STD-Zhang-2004" TYPE="STUDY">Zhang 2004</LINK>). However some adverse events have been reported. These include gastrointestinal tract symptoms, gingival bleeding, and increased partial thromboplastin time (<LINK REF="STD-Nong-2000" TYPE="STUDY">Nong 2000</LINK>). The effectiveness and adverse effects of such treatment needs to be reviewed systematically and appraised critically to inform the current practice and direct the continued search for new treatment regimens.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects (harms and benefits) of tongxinluo capsule for unstable angina. Specific comparisons were made between tongxinluo capsule with or without other treatments, compared with other treatments, placebo or no-treatment controls.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised controlled trials and quasi-randomised controlled trials were included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with a clinical diagnosis of unstable angina based on recognised diagnostic criteria including the Joint International Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature definition (<LINK REF="REF-Braunwald-1989" TYPE="REFERENCE">Braunwald 1989</LINK>) and the Canadian Cardiovascular Society modification (<LINK REF="REF-CCS-1972" TYPE="REFERENCE">CCS 1972</LINK>).<BR/>Participants were excluded if they had a history of acute myocardial infarction, heart failure, hepatic failure or renal failure. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Tongxinluo capsule, or routine treatment plus tongxinluo, will be compared with routine treatment, other anti-angina drugs, placebo or no intervention. The dose of tongxinluo capsule is 0.76g to 1.52g in 2 to 4 capsules (0.38g in each capsule) and administered 3 or 4 times, a total dose of between 2.28g to 6.0g per day. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>
<B>
<I>Primary outcome measures</I>
</B>
<BR/>(1) Rate of cardiovascular events include acute myocardial infarction (AMI) and percutaneous transluminal coronary balloon angioplasty (PTCA) or coronary artery bypass grafting (CABG)</P>
<P>
<B>
<I>Secondary outcome measures</I>
</B>
<BR/>(1) All cause mortality;<BR/>(2) Severity of angina pectoris;<BR/>(3) Frequency of acute attack angina;<BR/>(4) ECG improvement;<BR/>(5) Rate of dosage/frequency of use of nitroglycerine;<BR/>(6) Symptom improvement (such as chest distress, shorness of breath, hypodynamia, etc);<BR/>(7) Levels of serum cardiac troponin T (cTnT), creatinine kinase (CK) and isoenzyme MB (CK-MB);<BR/>(8) Levels of plasma endothelin level and nitric oxide;<BR/>(9) Health-related quality of life (ideally, using a validated instrument).</P>
<P>
<B>
<I>Adverse event outcome measures</I>
</B>
<BR/>Any adverse events as a result of treatment that (1) resulted in death, (2) were life-threatening, (3) produced a toxic response, for example, severe gastrointestinal tract reaction, gingival bleeding, and partial thromboplastin time longer than normal, (4) led to anaphylactic shock or (5) resulted in the discontinuation of treatment.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>A comprehensive and exhaustive search strategy was carried out including searching the electronic literature, hand searching journals and contacting drug companies and previous authors. The search was limited to the years since the development of tongxinluo (1995).</P>
<P>
<B>Electronic searches</B>
<BR/>The following electronic databases were searched using the terms 'tongxinluo', 'TXLC' and 'TXL':<BR/>The Cochrane Heart Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library, Issue 4, 2004, MEDLINE (1995 to 2004), EMBASE (1995 to 2004), Chinese Biomedical Database (CBM ,1995 to 2004), China National Knowledge Infrastructure (CNKI, 1994 to 2004), Japana Centra Revuo Medicina (1995 to 2005).</P>
<P>We also searched databases of ongoing trials: <BR/>Current Controlled Trials (www.controlled-trials.com) <BR/>The National Research Register (www.update-software.com/National/nrr-frame.html) </P>
<P>
<B>Handsearches<BR/>
</B>We handsearched the following Chinese traditional medicine Journals (1995 to 2004):<BR/>China Journal of Chinese Materia Medica<BR/>China Journal of Basic Medicine in Traditional Chinese Medicine<BR/>Chinese Journal of Integrated Traditional and Western Medicine<BR/>Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care<BR/>Chinese Journal of Traditional Medical Science and Technology<BR/>Chinese Journal of Traditional &amp; Western Medicine<BR/>Journal of Emergency in Traditional Chinese Medicine<BR/>Journal of Integrated Traditional and Western Medicine<BR/>Journal of Traditional Chinese Medicine<BR/>Journal of Emergency Syndromes in Chinese Medicine<BR/>Modern Journal of Integrated Chinese Traditional and Western Medicine<BR/>Modern Traditional Chinese Medicine<BR/>New Journal of Traditional Chinese Medicine<BR/>Traditional Chinese Medicine Research</P>
<P>We also searched the reference lists of relevant trials identified for any additional studies, and authors of identified studies were contacted to identify other studies.</P>
<P>
<B>Other search strategies</B>
<BR/>We contacted individual researchers working in the field and tongxinluo capsule manufacturers in order to obtain any additional references to unpublished trials, ongoing trials, confidential reports or raw data of published trials. </P>
<P>Studies in any language were eligible for inclusion.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>
<B>Trials Selection</B>
<BR/>Identified studies were assessed for eligibility for inclusion in the review based on scanning the titles, abstracts and keywords of every record retrieved. Full articles were retrieved for further assessment if the information suggested that the study: <BR/>(1) included patients with unstable angina;<BR/>(2) compared tongxinluo with any other active or placebo intervention;<BR/>(3) assessed one or more relevant clinical outcome measure;<BR/>(4) used random or pseudo random allocation to the comparison groups. <BR/>Articles were only rejected at this stage if they were definitely not relevant to the review.</P>
<P>WT and Chen Xiaoyan (Chen) independently assessed each of these trials for inclusion using an eligibility form based on the contents of the section 'Criteria for Inclusion'. There were no recorded disagreements. We excluded studies that did not meet the inclusion criteria and have stated the reasons in 'Characteristics of excluded studies'.</P>
<P>
<B>Quality assessment of trials<BR/>
</B>Eligible studies were assessed for quality based on the following criteria (<LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>):<BR/>(1) Randomisation -method of generation and concealment of allocation. Allocation generation considered adequate when the allocation sequence protects against biased allocation to the comparison gorups. Allocation concealment considered adequate when clinicians and participants are unaware of future allocations.<BR/>(2) Masking -blinding of observers / participants to the treatment allocation. Masking considered adequate when the outcome assessor is unaware of the allocation. <BR/>(3) Attrition -presence of dropouts and withdrawals, and the analysis of these. Attrition considered adequate when no more than 20% of participants were lost to follow up/withdraw/dropout, then analysed in the groups to which they were originally randomised (intention to treat).</P>
<P>Studies were divided into the following three categories: <BR/>A - all quality criteria met: low risk of bias; <BR/>B - one or more of the quality criteria only partly met: moderate risk of bias;<BR/>C - one or more criteria not met: high risk of bias.</P>
<P>Each trial selected for inclusion in the review was independently assessed by two reviewers (WU, CHEN). There were no recorded disagreements.</P>
<P>
<B>Data extraction</B>
<BR/>WT and Chen independently extracted data using a piloted data extraction form. We extracted data on study characteristics including methods, participants, interventions, and outcomes. We resolved any disagreements by referring to the trial report and through discussion.</P>
<P>
<B>Data analysis</B>
<BR/>We analysed the data using Review Manager (Version 4.2.7). We were only able to perform limited pooled analyses. We used a random effects model as heterogeneity was detected in combination analysis. We summarised dichotomous data as relative risk (RR). We reported continuous data as weighted mean difference (WMD). We used 95% confidence intervals throughout.</P>
<P>Non-randomised controlled studies have been listed but not discussed further. </P>
<P>We performed subgroup analyses based on variable interventions and comparisons, for example, tongxinluo + anti-angina routine treatment versus anti-angina routine treatment, and tongxinluo + low weight molecular heparin + anti-angina routine treatment versus low weight molecular heparin + anti-angina routine treatment.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>
<B>Studies identified</B>
<BR/>We initially found 42 controlled studies of tongxinluo capsule assessing the treatment of unstable angina pectoris. Nineteen studies were excluded for the following reasons (also see the Table of Excluded Studies): 5 studies were not random design (<LINK REF="STD-Hu-2001" TYPE="STUDY">Hu 2001</LINK>; <LINK REF="STD-Lu-2002b" TYPE="STUDY">Lu 2002b</LINK>; <LINK REF="STD-Qin-2004" TYPE="STUDY">Qin 2004</LINK>; <LINK REF="STD-Shi-2001" TYPE="STUDY">Shi 2001</LINK>; <LINK REF="STD-Xu-2003" TYPE="STUDY">Xu 2003</LINK>); 6 articles (<LINK REF="STD-Han-2004b" TYPE="STUDY">Han 2004b</LINK>; <LINK REF="STD-Li-2002" TYPE="STUDY">Li 2002</LINK>; <LINK REF="STD-Ma-2004" TYPE="STUDY">Ma 2004</LINK>; <LINK REF="STD-Su-2001" TYPE="STUDY">Su 2001</LINK>; <LINK REF="STD-Wang-2001" TYPE="STUDY">Wang 2001</LINK>; <LINK REF="STD-Yang-2002" TYPE="STUDY">Yang 2002</LINK>) adopted outcome measures which did not match the criteria in this review or data were unusable, 8 studies (<LINK REF="STD-Gao-2002" TYPE="STUDY">Gao 2002</LINK>; <LINK REF="STD-Huang-2004" TYPE="STUDY">Huang 2004</LINK>; <LINK REF="STD-Li-2000" TYPE="STUDY">Li 2000</LINK>; <LINK REF="STD-Li-2001" TYPE="STUDY">Li 2001</LINK>; <LINK REF="STD-Su-2004" TYPE="STUDY">Su 2004</LINK>; <LINK REF="STD-Wang-2003a" TYPE="STUDY">Wang 2003a</LINK>; <LINK REF="STD-Wang-2003b" TYPE="STUDY">Wang 2003b</LINK>; <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK>) included post AMI patients. Twenty three references to 18 studies fulfilled our inclusion criteria. All the studies were published in Chinese. We didn't find any ongoing studies.</P>
<P>
<B>Design of included studies</B>
<BR/>Details of the characteristics of the included studies are shown in the Table of Included Studies. All the included studies were of single centre, parallel design and had a control group. Fifteen of them mentioned randomisation and one study (<LINK REF="STD-Su-2000" TYPE="STUDY">Su 2000</LINK>) used quasi-randomisation. In this latter study, participants were allocated to the intervention or control group on the basis of order of going to the doctor. In all studies individuals formed the unit for allocation. Trial duration ranged from 10 days to 3 months. All the trials were conducted in China.</P>
<P>
<B>
<I>Participants in included studies<BR/>
</I>
</B>The number of participants in the studies ranged from 30 to 192, with a total of 1413 in the 18 studies in this review. The age of participants ranged from 25 to 88 years with mean ages, where given, ranging from 50 to 65 years. Seven studies (<LINK REF="STD-Han-2004a" TYPE="STUDY">Han 2004a</LINK>; <LINK REF="STD-Jia-2001" TYPE="STUDY">Jia 2001</LINK>; <LINK REF="STD-Liang-2002" TYPE="STUDY">Liang 2002</LINK>; <LINK REF="STD-Sun-2004" TYPE="STUDY">Sun 2004</LINK>; <LINK REF="STD-Wang-2003a" TYPE="STUDY">Wang 2003a</LINK>; <LINK REF="STD-Xiao-2004" TYPE="STUDY">Xiao 2004</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>) mentioned the duration of unstable angina, which ranged from one to 12 years. </P>
<P>
<B>
<I>Interventions in included studies</I>
</B>
<BR/>
</P>
<UL>
<LI>Eleven studies (<LINK REF="STD-Chang-2004" TYPE="STUDY">Chang 2004</LINK>; <LINK REF="STD-Cheng-2002" TYPE="STUDY">Cheng 2002</LINK>; <LINK REF="STD-Jia-2001" TYPE="STUDY">Jia 2001</LINK>; <LINK REF="STD-Liu-2003" TYPE="STUDY">Liu 2003</LINK>; <LINK REF="STD-Nong-2000" TYPE="STUDY">Nong 2000</LINK>; <LINK REF="STD-Su-2000" TYPE="STUDY">Su 2000</LINK>; <LINK REF="STD-Sun-2004" TYPE="STUDY">Sun 2004</LINK>; <LINK REF="STD-Xiao-2002" TYPE="STUDY">Xiao 2002</LINK>; <LINK REF="STD-Xiao-2004" TYPE="STUDY">Xiao 2004</LINK>; <LINK REF="STD-Yao-2003" TYPE="STUDY">Yao 2003</LINK>; <LINK REF="STD-Zhang-2000" TYPE="STUDY">Zhang 2000</LINK>) compared routine treatment plus tongxinluo to routine anti-angina treatment </LI>
<LI>One study (<LINK REF="STD-Liang-2002" TYPE="STUDY">Liang 2002</LINK>) compared anti-angina routine treatment plus tongxinluo to anti-angina routine treatment plus danshen</LI>
<LI>Four studies (<LINK REF="STD-Han-2004a" TYPE="STUDY">Han 2004a</LINK>; <LINK REF="STD-Jia-1999" TYPE="STUDY">Jia 1999</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Zhang-2004" TYPE="STUDY">Zhang 2004</LINK>) compared tongxinluo capsule to isosorbide mononitrate </LI>
<LI>Two studies (<LINK REF="STD-Lu-2002a" TYPE="STUDY">Lu 2002a</LINK>, <LINK REF="STD-Song-2002" TYPE="STUDY">Song 2002</LINK>) compared routine anti-angina treatment plus low weight molecular heparin (LWMH) plus tongxinluo to routine treatment plus LWMH. The drugs of routine anti-angina treatment included single or combined use of aspirin, beta-blockers, nitrates (nitroglycerin) and xiaoxintong (isosorbide dinitrate), calcium channel blockers and ACEI</LI>
</UL>
<P>
<BR/>Tongxinluo was given in the form of capsules to be taken orally three times a day. Doses varied between the included studies:<BR/>
</P>
<UL>
<LI>Two studies (<LINK REF="STD-Jia-1999" TYPE="STUDY">Jia 1999</LINK>, <LINK REF="STD-Zhang-2004" TYPE="STUDY">Zhang 2004</LINK>) gave two capsules at a time </LI>
<LI>Six studies (<LINK REF="STD-Chang-2004" TYPE="STUDY">Chang 2004</LINK>; <LINK REF="STD-Cheng-2002" TYPE="STUDY">Cheng 2002</LINK>; <LINK REF="STD-Wang-2003a" TYPE="STUDY">Wang 2003a</LINK>; <LINK REF="STD-Su-2000" TYPE="STUDY">Su 2000</LINK>; <LINK REF="STD-Sun-2004" TYPE="STUDY">Sun 2004</LINK>; <LINK REF="STD-Yao-2003" TYPE="STUDY">Yao 2003</LINK>) gave three capsules at a time </LI>
<LI>Ten studies (<LINK REF="STD-Han-2004a" TYPE="STUDY">Han 2004a</LINK>, <LINK REF="STD-Jia-2001" TYPE="STUDY">Jia 2001</LINK>, <LINK REF="STD-Liang-2002" TYPE="STUDY">Liang 2002</LINK>, <LINK REF="STD-Liu-2003" TYPE="STUDY">Liu 2003</LINK>, <LINK REF="STD-Lu-2002a" TYPE="STUDY">Lu 2002a</LINK>, <LINK REF="STD-Nong-2000" TYPE="STUDY">Nong 2000</LINK>, <LINK REF="STD-Song-2002" TYPE="STUDY">Song 2002</LINK>, <LINK REF="STD-Xiao-2002" TYPE="STUDY">Xiao 2002</LINK>, <LINK REF="STD-Xiao-2004" TYPE="STUDY">Xiao 2004</LINK>, <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>) gave four capsules at a time.</LI>
</UL>
<P>
<BR/>Length of treatment ranged from ten days to three months <BR/>
</P>
<UL>
<LI>One study (<LINK REF="STD-Song-2002" TYPE="STUDY">Song 2002</LINK>) treated 10 days</LI>
<LI>Two studies (<LINK REF="STD-Liu-2003" TYPE="STUDY">Liu 2003</LINK>; <LINK REF="STD-Lu-2002a" TYPE="STUDY">Lu 2002a</LINK>), treated for two weeks</LI>
<LI>One study (<LINK REF="STD-Su-2000" TYPE="STUDY">Su 2000</LINK>) treated for 15 days</LI>
<LI>One study (<LINK REF="STD-Xiao-2004" TYPE="STUDY">Xiao 2004</LINK>) treated for three weeks</LI>
<LI>Nine studies (<LINK REF="STD-Cheng-2002" TYPE="STUDY">Cheng 2002</LINK>; <LINK REF="STD-Han-2004a" TYPE="STUDY">Han 2004a</LINK>; <LINK REF="STD-Jia-1999" TYPE="STUDY">Jia 1999</LINK>; <LINK REF="STD-Jia-2001" TYPE="STUDY">Jia 2001</LINK>; <LINK REF="STD-Xiao-2002" TYPE="STUDY">Xiao 2002</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Yao-2003" TYPE="STUDY">Yao 2003</LINK>; <LINK REF="STD-Zhang-2000" TYPE="STUDY">Zhang 2000</LINK>; <LINK REF="STD-Zhang-2004" TYPE="STUDY">Zhang 2004</LINK>) treated for four weeks</LI>
<LI>One study (<LINK REF="STD-Chang-2004" TYPE="STUDY">Chang 2004</LINK>) treated for six weeks</LI>
<LI>One study (<LINK REF="STD-Wang-2003a" TYPE="STUDY">Wang 2003a</LINK>) treated for two months</LI>
<LI>One study (<LINK REF="STD-Liang-2002" TYPE="STUDY">Liang 2002</LINK>) treated for three months</LI>
<LI>One study (<LINK REF="STD-Nong-2000" TYPE="STUDY">Nong 2000</LINK>) did not provide information on treatment duration.</LI>
</UL>
<P> <BR/>
<B>
<I>Outcome measures of included studies<BR/>
</I>
</B>
</P>
<UL>
<LI>Three studies (<LINK REF="STD-Lu-2002a" TYPE="STUDY">Lu 2002a</LINK>; <LINK REF="STD-Nong-2000" TYPE="STUDY">Nong 2000</LINK>; <LINK REF="STD-Su-2000" TYPE="STUDY">Su 2000</LINK>) reported on the incidence of acute myocardial infarction (AMI) and percutaneous transluminal coronary balloon angioplasty (PTCA) or coronary artery bypass grafting (CABG) </LI>
<LI>One study (<LINK REF="STD-Nong-2000" TYPE="STUDY">Nong 2000</LINK>) reported on sudden death. </LI>
<LI>Thirteen studies (<LINK REF="STD-Chang-2004" TYPE="STUDY">Chang 2004</LINK>; <LINK REF="STD-Cheng-2002" TYPE="STUDY">Cheng 2002</LINK>; <LINK REF="STD-Jia-1999" TYPE="STUDY">Jia 1999</LINK>; <LINK REF="STD-Jia-2001" TYPE="STUDY">Jia 2001</LINK>; <LINK REF="STD-Liu-2003" TYPE="STUDY">Liu 2003</LINK>; <LINK REF="STD-Lu-2002a" TYPE="STUDY">Lu 2002a</LINK>; <LINK REF="STD-Su-2000" TYPE="STUDY">Su 2000</LINK>; <LINK REF="STD-Sun-2004" TYPE="STUDY">Sun 2004</LINK>; <LINK REF="STD-Xiao-2002" TYPE="STUDY">Xiao 2002</LINK>; <LINK REF="STD-Xiao-2004" TYPE="STUDY">Xiao 2004</LINK>; <LINK REF="STD-Yao-2003" TYPE="STUDY">Yao 2003</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Zhang-2004" TYPE="STUDY">Zhang 2004</LINK>) assessed rates of both improvement, no improvement and worsening of symptoms.</LI>
<LI>Ten studies (<LINK REF="STD-Chang-2004" TYPE="STUDY">Chang 2004</LINK>; <LINK REF="STD-Cheng-2002" TYPE="STUDY">Cheng 2002</LINK>; <LINK REF="STD-Jia-1999" TYPE="STUDY">Jia 1999</LINK>; <LINK REF="STD-Jia-2001" TYPE="STUDY">Jia 2001</LINK>; <LINK REF="STD-Song-2002" TYPE="STUDY">Song 2002</LINK>; <LINK REF="STD-Su-2000" TYPE="STUDY">Su 2000</LINK>; <LINK REF="STD-Sun-2004" TYPE="STUDY">Sun 2004</LINK>; <LINK REF="STD-Xiao-2004" TYPE="STUDY">Xiao 2004</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Zhang-2004" TYPE="STUDY">Zhang 2004</LINK>) assessed any ECG improvement.</LI>
<LI>Two studies (<LINK REF="STD-Han-2004a" TYPE="STUDY">Han 2004a</LINK>, <LINK REF="STD-Jia-1999" TYPE="STUDY">Jia 1999</LINK>) assessed level of plasma nitric oxide (NO) </LI>
<LI>Four studies (<LINK REF="STD-Han-2004a" TYPE="STUDY">Han 2004a</LINK>, <LINK REF="STD-Jia-1999" TYPE="STUDY">Jia 1999</LINK>, <LINK REF="STD-Liang-2002" TYPE="STUDY">Liang 2002</LINK>; <LINK REF="STD-Zhang-2004" TYPE="STUDY">Zhang 2004</LINK>) assessed endothelin (ET) level </LI>
<LI>One study (<LINK REF="STD-Zhang-2000" TYPE="STUDY">Zhang 2000</LINK>), reported nitroglycerine consumption using the number of people stopping or reducing by half the dosage in</LI>
<LI>Two studies (<LINK REF="STD-Cheng-2002" TYPE="STUDY">Cheng 2002</LINK>, <LINK REF="STD-Nong-2000" TYPE="STUDY">Nong 2000</LINK>) measured of reduction in dosages</LI>
<LI>One study (<LINK REF="STD-Nong-2000" TYPE="STUDY">Nong 2000</LINK>) evaluated angina scores</LI>
<LI>Five studies (<LINK REF="STD-Cheng-2002" TYPE="STUDY">Cheng 2002</LINK>, <LINK REF="STD-Han-2004a" TYPE="STUDY">Han 2004a</LINK>, <LINK REF="STD-Song-2002" TYPE="STUDY">Song 2002</LINK>, <LINK REF="STD-Xiao-2004" TYPE="STUDY">Xiao 2004</LINK>, <LINK REF="STD-Zhang-2004" TYPE="STUDY">Zhang 2004</LINK>) reported frequency of angina attacks </LI>
<LI>One study (<LINK REF="STD-Nong-2000" TYPE="STUDY">Nong 2000</LINK>) described levels of serum cardiac troponin T (cTnT), creatinine kinase (CK) and isoenzyme MB (CK-MB) but no useable data were available </LI>
<LI>Three studies (<LINK REF="STD-Jia-1999" TYPE="STUDY">Jia 1999</LINK>, <LINK REF="STD-Lu-2002a" TYPE="STUDY">Lu 2002a</LINK>, <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>) assessed adverse effects on liver and renal function but no useable data were available</LI>
<LI>None of the studies mentioned health-related quality of life.</LI>
</UL>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>All of the included trials were of low quality ('C'). An overview of study quality can be found in the Characteristics of Included Studies table.</P>
<P>
<B>Randomisation</B>
<BR/>All the included studies mentioned randomisation except one (<LINK REF="STD-Su-2000" TYPE="STUDY">Su 2000</LINK>) which was a quasi-randomised controlled trial. However, only one study (<LINK REF="STD-Liang-2002" TYPE="STUDY">Liang 2002</LINK>) described an allocation sequence being generated from random number tables. None of the others described the method of randomisation in detail. None of the included studies mentioned allocation concealment. We tried to interview the authors of studies by telephone for more detailed information but none of them were available. We then wrote to the authors but did receive any replies.</P>
<P>
<B>Blinding</B>
<BR/>None of the studies mentioned blinding.</P>
<P>
<B>Description of withdrawals and losses to follow up and intention-to-treat analysis</B>
<BR/>Withdrawals and losses to follow up were described by one study (<LINK REF="STD-Jia-1999" TYPE="STUDY">Jia 1999</LINK>). None of the studies performed intention-to-treat analysis.</P>
<P>
<B>Compliance assessment</B>
<BR/>None of the studies mentioned any methods of assessing compliance. However ,one study (<LINK REF="STD-Jia-1999" TYPE="STUDY">Jia 1999</LINK>) mentioned there were withdrawals due to poor compliance.</P>
<P>
<B>Similarity of comparison groups at baseline</B>
<BR/>Age and gender were considered important factors and appeared to be balanced across treatment/control groupings. Six studies (<LINK REF="STD-Han-2004a" TYPE="STUDY">Han 2004a</LINK>; <LINK REF="STD-Jia-1999" TYPE="STUDY">Jia 1999</LINK>; <LINK REF="STD-Jia-2001" TYPE="STUDY">Jia 2001</LINK>; <LINK REF="STD-Su-2000" TYPE="STUDY">Su 2000</LINK>; <LINK REF="STD-Sun-2004" TYPE="STUDY">Sun 2004</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>) reported the duration of UA. Five studies (<LINK REF="STD-Chang-2004" TYPE="STUDY">Chang 2004</LINK>; <LINK REF="STD-Jia-1999" TYPE="STUDY">Jia 1999</LINK>; <LINK REF="STD-Liang-2002" TYPE="STUDY">Liang 2002</LINK>; <LINK REF="STD-Su-2000" TYPE="STUDY">Su 2000</LINK>; <LINK REF="STD-Zhang-2000" TYPE="STUDY">Zhang 2000</LINK>) compared the similarity of severity of disease between study groups.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>
<B>Primary outcome measures</B>
</P>
<P>
<B>
<I>1. Rate of cardiovascular events</I>
</B>
<BR/>Two trials (<LINK REF="STD-Nong-2000" TYPE="STUDY">Nong 2000</LINK>, <LINK REF="STD-Su-2000" TYPE="STUDY">Su 2000</LINK>) had relevant data on cardiovascular events in comparions of tongxinluo with usual care but had imprecise findings consistent with both benefit and harm, reflecting the small sample sizes, and also demonstrated some heterogeneity in the pooled estimate (RR 0.42, 95% CI 0.07 to 2.59, P=0.35, I<SUP>2</SUP> =71.4%, p=0.06). A single study (<LINK REF="STD-Lu-2002a" TYPE="STUDY">Lu 2002a</LINK>) showed that the addition of tongxinluo to low molecular weight heparin (LMWH) was no better or worse at reducing cardiovascular events (RR 0.12, 95%CI 0.01~1.92, P=0.13), but as with the other two trials, the estimate of effect was imprecise.</P>
<P>
<B>Secondary outcome measures<BR/>
</B>
<BR/>
<B>
<I>1. Sudden death</I>
</B>
<BR/>Limited data from one study (<LINK REF="STD-Nong-2000" TYPE="STUDY">Nong 2000</LINK>) showed that tongxinluo was no better or worse at reducing the risk of sudden death than routine treatment alone (RR 0.33; 95%CI 0.01 to 7.78, P=0.49).</P>
<P>
<B>
<I>2. Severity of angina pectoris: angina scores<BR/>
</I>
</B>Data from one study (<LINK REF="STD-Nong-2000" TYPE="STUDY">Nong 2000</LINK>) showed that tongxinluo was no better or worse at reducing angina scores routine treatment alone (WMD -1.04, 95%CI -2.33 to 0.25, P=0.11).</P>
<P>
<B>
<I>3. Frequency of acute attack angina</I>
</B>
<BR/>Strong evidence from one study (<LINK REF="STD-Song-2002" TYPE="STUDY">Song 2002</LINK>) showed that tongxinluo or addition of tongxinluo to LMWH reduced the frequency of acute attack angina (WMD -1.20, 95%CI -1.38 to -1.02, P&lt;0.00001). This effect was supported by two trials (<LINK REF="STD-Cheng-2002" TYPE="STUDY">Cheng 2002</LINK>; <LINK REF="STD-Xiao-2004" TYPE="STUDY">Xiao 2004</LINK>) comparing tongxinluo with usual care in which frequency of angina attacks was also shown to be reduced markedly (WMD -5.41, 95%CI -5.74 to -5.08, and WMD -1.16, 95%CI -1.37 to -0.95, respectively). However, in the comparison of tongxinluo with isosorbide mononitrate, adverse results appeared in two studies (WMD 0.30, 95%CI 0.02 to 0.58, and WMD -0.92, 95%CI -1.17 to -0.67, respectively)(<LINK REF="STD-Han-2004a" TYPE="STUDY">Han 2004a</LINK>; <LINK REF="STD-Zhang-2004" TYPE="STUDY">Zhang 2004</LINK>). We did not perform pooled analysis because of the high levels of heterogeneity in these studies.</P>
<P>
<B>
<I>4. ECG improvement<BR/>
</I>
</B>
<I>(1). Rate of marked improvement of ECG<BR/>
</I>Some evidence showed that tongxinluo improved ECG (RR 1.31, 95%CI 1.08 to 1.57, P=0.005). Data was pooled from seven studies (<LINK REF="STD-Chang-2004" TYPE="STUDY">Chang 2004</LINK>; <LINK REF="STD-Cheng-2002" TYPE="STUDY">Cheng 2002</LINK>; <LINK REF="STD-Jia-2001" TYPE="STUDY">Jia 2001</LINK>; <LINK REF="STD-Su-2000" TYPE="STUDY">Su 2000</LINK>; <LINK REF="STD-Sun-2004" TYPE="STUDY">Sun 2004</LINK>; <LINK REF="STD-Xiao-2004" TYPE="STUDY">Xiao 2004</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>). There was no heterogeneity (P=0.74, I<SUP>2</SUP>=0%).</P>
<P>Weak evidence from pooled analysis across three studies (<LINK REF="STD-Jia-1999" TYPE="STUDY">Jia 1999</LINK>, <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>, <LINK REF="STD-Zhang-2004" TYPE="STUDY">Zhang 2004</LINK>) showed that tongxinluo was better at marked improvement of ECG than isosorbide mononitrate (RR 1.37, 95%CI 1.04 to 1.81, P=0.02). There was no heterogeneity (P=0.93, I<SUP>2</SUP>=0%).</P>
<P>A single study (<LINK REF="STD-Song-2002" TYPE="STUDY">Song 2002</LINK>) showed that addition of tongxinluo to LMWH was no better or worse at marked improvement of ECG (WMD 1.38, 95%CI 0.64 to 2.93, P=0.41). </P>
<P>(2). <I>Rate of no improvement or worsening of ECG<BR/>
</I>Strong evidence from pooled analysis across six studies (<LINK REF="STD-Cheng-2002" TYPE="STUDY">Cheng 2002</LINK>; <LINK REF="STD-Jia-2001" TYPE="STUDY">Jia 2001</LINK>; <LINK REF="STD-Su-2000" TYPE="STUDY">Su 2000</LINK>; <LINK REF="STD-Sun-2004" TYPE="STUDY">Sun 2004</LINK>; <LINK REF="STD-Xiao-2004" TYPE="STUDY">Xiao 2004</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>) showed that tongxinluo reduced the number of people with no improvement or worsening of ECG (RR 0.68, 95%CI 0.56 to 0.82, P&lt;0.0001). There was no heterogeneity (P =0.20, I<SUP>2</SUP> =30.7%).</P>
<P>Tongxinluo was no better or worse at reducing the number of people with no improvement or worsening of ECG than isosorbide mononitrate (RR 0.73, 95%CI 0.43 to 1.24, P=0.25). Data was pooled from three studies (<LINK REF="STD-Jia-1999" TYPE="STUDY">Jia 1999</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Zhang-2004" TYPE="STUDY">Zhang 2004</LINK>) there was no heterogeneity (P=0.60, I<SUP>2</SUP>=0%).</P>
<P>A single study (<LINK REF="STD-Song-2002" TYPE="STUDY">Song 2002</LINK>) showed that the addition of tongxinluo to LMWH was no better or worse at reducing the number of people with no improvement or worsening of ECG (RR 0.86, 95%CI 0.61 to 1.22, P=0.41).</P>
<P>
<B>
<I>5. Consumption of nitroglycerine</I>
</B>
<BR/>Weak evidence from a single study (<LINK REF="STD-Zhang-2000" TYPE="STUDY">Zhang 2000</LINK>) showed that tongxinluo increased both the number of withdrawals, and the reduction of dosage by half, of nitroglycerin (RR 2.0, 95%CI 1.15 to 3.49, P=0.01 and RR 1.22, 95%CI 1.01 to 1.47, P=0.04, respectively). Also, tongxinluo reduced the consumption of nitroglycerin. Data were not pooled for 2 studies (<LINK REF="STD-Cheng-2002" TYPE="STUDY">Cheng 2002</LINK>; <LINK REF="STD-Nong-2000" TYPE="STUDY">Nong 2000</LINK>) due to marked heterogeneity.</P>
<P>
<B>
<I>6. Symptom improvement<BR/>
</I>
</B>(<I>1). Rate of marked improvement of symptoms<BR/>
</I>Tongxinluo improved angina symptoms (RR 1.21, 95% CI 1.06 to 1.40; P=0.007). Data were pooled from 10 studies (<LINK REF="STD-Chang-2004" TYPE="STUDY">Chang 2004</LINK>; <LINK REF="STD-Cheng-2002" TYPE="STUDY">Cheng 2002</LINK>; <LINK REF="STD-Jia-2001" TYPE="STUDY">Jia 2001</LINK>; <LINK REF="STD-Liu-2003" TYPE="STUDY">Liu 2003</LINK>; <LINK REF="STD-Su-2000" TYPE="STUDY">Su 2000</LINK>; <LINK REF="STD-Sun-2004" TYPE="STUDY">Sun 2004</LINK>; <LINK REF="STD-Xiao-2002" TYPE="STUDY">Xiao 2002</LINK>; <LINK REF="STD-Xiao-2004" TYPE="STUDY">Xiao 2004</LINK>; <LINK REF="STD-Yao-2003" TYPE="STUDY">Yao 2003</LINK>; <LINK REF="STD-Zhang-2000" TYPE="STUDY">Zhang 2000</LINK>). There was no heterogeneity (P =0.49, I<SUP>2</SUP> =0%).</P>
<P>Tongxinluo was no better or worse at relieving symptoms of angina than isosorbide mononitrate (RR 1.04; 95% CI 0.83 to 1.30, P=0.73). Data were pooled from 3 studies (<LINK REF="STD-Jia-1999" TYPE="STUDY">Jia 1999</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Zhang-2004" TYPE="STUDY">Zhang 2004</LINK>). There was no heterogeneity (P =0.67 I<SUP>2</SUP> =0%).</P>
<P>A single study (<LINK REF="STD-Lu-2002a" TYPE="STUDY">Lu 2002a</LINK>) showed that the addition of tongxinluo to LMWH was no better or worse at relieving symptoms of angina (RR 1.58, 95%CI 0.79 to 3.16, P=0.2). </P>
<P>(2). Rate of no improvement or worsening of symptoms<BR/>Tongxinluo reduced the number of people showing no improvement or worsening of symptoms (RR 0.45, 95%CI 0.33 to 0.62, P&lt;0.00001). Data were pooled from nine studies (<LINK REF="STD-Chang-2004" TYPE="STUDY">Chang 2004</LINK>; <LINK REF="STD-Cheng-2002" TYPE="STUDY">Cheng 2002</LINK>; <LINK REF="STD-Jia-2001" TYPE="STUDY">Jia 2001</LINK>; <LINK REF="STD-Liu-2003" TYPE="STUDY">Liu 2003</LINK>; <LINK REF="STD-Su-2000" TYPE="STUDY">Su 2000</LINK>; <LINK REF="STD-Sun-2004" TYPE="STUDY">Sun 2004</LINK>; <LINK REF="STD-Xiao-2002" TYPE="STUDY">Xiao 2002</LINK>; <LINK REF="STD-Xiao-2004" TYPE="STUDY">Xiao 2004</LINK>; <LINK REF="STD-Yao-2003" TYPE="STUDY">Yao 2003</LINK>) there was no heterogeneity (P=0.52, I<SUP>2</SUP>=0%).</P>
<P>Tongxinluo was no better or worse at relieving symptoms of angina than isosorbide mononitrate (RR 0.59; 95% CI 0.28 to 1.23, P=0.16). Data were pooled from three studies (<LINK REF="STD-Jia-1999" TYPE="STUDY">Jia 1999</LINK>, <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>, <LINK REF="STD-Zhang-2004" TYPE="STUDY">Zhang 2004</LINK>). There was no heterogeneity (p =0.18 I<SUP>2</SUP> =41.6%).</P>
<P>Weak evidence from a single study (<LINK REF="STD-Lu-2002a" TYPE="STUDY">Lu 2002a</LINK>) showed that the addition of tongxinluo to LMWH reduced the number of people showing no improvement (RR 0.27, 95% CI 0.08 to 0.88 P=0.03). </P>
<P>
<B>
<I>7. Level of endothelin<BR/>
</I>
</B>Strong evidence from pooled analysis across three studies (<LINK REF="STD-Han-2004b" TYPE="STUDY">Han 2004b</LINK>; <LINK REF="STD-Jia-1999" TYPE="STUDY">Jia 1999</LINK>; <LINK REF="STD-Zhang-2004" TYPE="STUDY">Zhang 2004</LINK>) showed that both tongxinluo and isosorbide mononitrate reduced the level of endothelin (WMD -15.48, 95%CI -17.94 to -13.03, P&lt;0.00001, and WMD -14.01, 95%CI -16.37 to -11.66, P&lt;0.00001, respectively). However there appeared to be no difference in the effect of tongxinluo compared to isosorbide mononitrate (WMD -1.50, 95%CI -3.93 to 0.94, P=0.23). There was no heterogeneity between the studies (P=0.92, I<SUP>2</SUP>=0%).</P>
<P>Weak evidence from a single study (<LINK REF="STD-Liang-2002" TYPE="STUDY">Liang 2002</LINK>) showed that tongxinluo reduced the level of endothelin compared to danshen compounds (RR -6.28, 95%CI-12.00 to -0.56, P=0.03). </P>
<P>
<B>
<I>8. Level of nitric oxide</I>
</B>
<BR/>Evidence from pooled analysis across two studies (<LINK REF="STD-Han-2004b" TYPE="STUDY">Han 2004b</LINK>; <LINK REF="STD-Jia-1999" TYPE="STUDY">Jia 1999</LINK>) showed that both tongxinluo and isosorbide mononitrate increased the serum level of nitric oxide (WMD 9.10, 95%CI 8.21 to 9.99, P&lt;0.00001 and WMD 8.04, 95%CI 4.93 to 11.16, P&lt;0.00001, respectively). However there was no difference between the effect of tongxinluo and that of isosorbide mononitrate (WMD 1.08, 95%CI -2.03 to 4.19, P=0.50). There was heterogeneity (P =0.002, I<SUP>2</SUP> =89.8%).</P>
<P>
<B>
<I>9. Quality of life</I>
</B>
<BR/>None of the studies analysed quality of life.</P>
<P>
<B>
<I>10. Adverse effects</I>
</B>
<BR/>A few cases of slight gastrointestinal discomfort were reported in seven studies (<LINK REF="STD-Jia-1999" TYPE="STUDY">Jia 1999</LINK>; <LINK REF="STD-Jia-2001" TYPE="STUDY">Jia 2001</LINK>; <LINK REF="STD-Nong-2000" TYPE="STUDY">Nong 2000</LINK>; <LINK REF="STD-Song-2002" TYPE="STUDY">Song 2002</LINK>; <LINK REF="STD-Sun-2004" TYPE="STUDY">Sun 2004</LINK>; <LINK REF="STD-Xiao-2002" TYPE="STUDY">Xiao 2002</LINK>; <LINK REF="STD-Xiao-2004" TYPE="STUDY">Xiao 2004</LINK>) and three cases of ecchymosis in one study (<LINK REF="STD-Lu-2002a" TYPE="STUDY">Lu 2002a</LINK>) after giving tongxinluo capsule. There were no other recorded adverse effects.</P>
<P>
<B>
<I>Subgroup analysis</I>
</B>
<BR/>The duration of follow up was shorter than four weeks in 15 of the 18 included studies. Most studies did not report outcomes separately for up to seven days or longer than seven days. We were therefore unable to analyse studies according to short or long term follow up. </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>
<B>Summary of main results (benefits and harms)</B>
<BR/>Eighteen randomised controlled trials were found and most of these had fewer than 100 participants. All the studies were classified as being of low quality. As shown above, there was marked heterogeneity in pooled analysis on frequency of angina attacks (<LINK REF="STD-Cheng-2002" TYPE="STUDY">Cheng 2002</LINK>; <LINK REF="STD-Xiao-2004" TYPE="STUDY">Xiao 2004</LINK>) and nitro-glycerine consumption (<LINK REF="STD-Han-2004a" TYPE="STUDY">Han 2004a</LINK>; <LINK REF="STD-Zhang-2004" TYPE="STUDY">Zhang 2004</LINK>) which may be due to differences in study design.</P>
<P>Therefore, we are unable to draw a conclusion on the impact of the routine use of anti-angina treatment with tongxinluo capsule in reducing the incidence of acute myocardial infarction, percutaneous transluminal coronary balloon angioplasty or coronary artery bypass grafting.</P>
<P>However, the addition of tongxinluo to routine treatment appeared to have some benefit showing an increase in the rate of marked improvement, and also a higher rate of ECG improvement. In addition, the use of tongxinluo was associated with a significant trend in reduction of the need for nitroglycerin. When tongxinluo was compared to isosorbide mononitrate, the effects on sypmptoms appeared similar but there was a higher rate of ECG improvement in those treated with tongxinluo. In one study comparing tongxinluo capsule to danshen compounds, both in addition to routine anti-angina treatment, routine anti-angina treatment plus tongxinluo showed a statistically significant decrease of ET (<LINK REF="STD-Liang-2002" TYPE="STUDY">Liang 2002</LINK>). When tongxinluo was added to routine treatment plus LMWH there appeared to be benefits with a reduction in the number of angina attacks and in the rate of deterioration in symptoms.</P>
<P>
<B>Limitations of included studies and the review</B>
<BR/>There are a number of limitations in this review. <BR/>1. Only Chinese language publications were found and included. <BR/>2. The number of participants in most studies was generally small, studies assessed different outcome measures and, for some outcomes, only a single study provided data. <BR/>3. The included studies were of poor methodological quality and neither blinding nor allocation concealment were used in any of the studies. This could lead to a high risk of both selection bias and detection bias. We will make further attempts to contact relevant authors for detailed information of allocation concealment and randomisation for an update of this review in the future. <BR/>4. The overall analysis of some parameters ignored the varying trial durations and the varying drug usage of routine treatments. This may have resulted in some clinical heterogeneity between studies. <BR/>5. The inclusion criteria in different trials was rather variable, leading to some doubt that only patients with unstable angina were included.<BR/>6. None of included studies mentioned ethical issues or whether the participants gave informed consent.<BR/>7. The comparator treatment in some trials was probably sub-optimal with some only receiving nitrates, and not LMWH or other effective regimens (<LINK REF="REF-ICSI-2005b" TYPE="REFERENCE">ICSI 2005b</LINK>). Consequenlty, tongxinluo may have shown more beneficial effects in such trials.</P>
<P>
<B>Generalisability and applicability of results</B>
<BR/>Although this review shows that there appears to be some benefit from the use of tongxinluo, the results should be interpreted with caution because of the poor methodology of the included studies, and potential clinical heterogeneity. In addition, the number of studies found reporting some individual outcomes was small and more evidence is needed before coming to any firm conclusions about the effects of tongxinlou. Although there were no recorded adverse reactions, the safety of using tongxinlou is still to be proved.</P>
<P>Tongxinluo contains not only medicinal plants extracts but also animal products such as scorpion, leech, and centipede. The latter are not permitted to be used as therapeutic agents in most western countries. In addition, although the treatment and its method of manufacture are widely accepted in China, most of the constituents of the pharmacological preparations used in the trials cannot be specified precisely. This is in marked contrast to industrially-manufactured pharmacological agents used in Western medicine, in which the chemical constituents, their quantities, and the percentage of any impurities or contaminants are very precisely known; and the variation between different production batches is kept within specified limits. Variation between formulations and batches of treatment is an inevitable consequence of the nature of Chinese Traditional Medicines, though the Chinese Government also specifies the limits of variation that are acceptable. This variation is a factor that may contribute to any heterogeneity between different study results. Furthermore, one must accept that the overall treatment concept for Chinese Traditional Medicine is different to that used in Western medicine.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>It is possible that tongxinlou, added to routine treatment, has some benefit for people with unstable angina. However, lack of evidence means that it should be used with caution.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>More high quality randomised controlled trials following the CONSORT criteria are required for assessing the effects of adding tongxinlou to routine anti-angina treatment for unstable angina. Relevant clinical events such as AMI and death should be included in outcomes assessed in these studies, and adverse reactions should be investigated to assess safety.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We thank Theresa Moore, Coordinator of Cochrane Heart Group, Margaret Burke, Trials Search Coordinator and Shah Ebrahim, for advice in writing this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Taixiang Wu was responsible for maintaining and developing both the protocol and review . He also organised the review team and communicated with the editorial base. Roger A Harrison drafted the protocol and the review. Xiaoyan Chen contributed to the analysis of the data and drafting the review. Liqun Zhou contributed to the trials search, quality assessment of trials, data extraction and data analysis. Jiafu Wei, Qin Wang, Juan Ni, Xin Duan, Jie Zheng, Jieqi Qiao contributed to the trials search.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2013-01-23 11:52:22 +0000" MODIFIED_BY="[Empty name]">
<P>Authors unable to update.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-2004" NAME="Chang 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang SF, Zhao M</AU>
<TI>Effects of tongxinluo capsule in the treatment of 68 patients with unstable angina pectoris</TI>
<SO>Modern Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>2</NO>
<PG>189</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2002" NAME="Cheng 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng GL, Yang WL</AU>
<TI>Use of Tongxinluo capsule in patients of unstable angina pectoris</TI>
<SO>Chinese Journal of the Practical Chinese with Modern Medicine</SO>
<YR>2002</YR>
<VL>2(15)</VL>
<NO>5</NO>
<PG>504</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Han-2004a" NAME="Han 2004a" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Han HP, Zhang XR</AU>
<TI>Effect of tongxinluo capsule on function of vascular endothelium in patients with unstable angina pectoris</TI>
<SO>Modern Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>3</NO>
<PG>307</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jia-1999" NAME="Jia 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jia Z, Gu FS, Xue YF</AU>
<TI>Effect of Tongxinluo capsule in treating variant angina pectoris patients and its influence on endothelial function</TI>
<SO>Chinese Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>11</NO>
<PG>651-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jia-2001" NAME="Jia 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jia ZM, Qi GX, Zhen DY</AU>
<TI>Study of therapeutic effect of Tongxinluo (TXL) capsule and its therapeutical mechanism</TI>
<SO>Journal of Integrated Modern Chinese and Western Medicine</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>11</NO>
<PG>997-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jia ZM, Qi GX, Zheng DY</AU>
<TI>Study of therapeutic effect of TongXinLuo (TXL) capsule and its therapeutical mechanism</TI>
<SO>Chinese Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>5</NO>
<PG>689-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jia ZM, Zhu J, Qi GX</AU>
<TI>Effect of Tongxinluo capsule on function of vascular endothelium in patients with coronary heart disease</TI>
<SO>Chinese Famous Doctor Forum</SO>
<YR>2003</YR>
<NO>11</NO>
<PG>10-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liang-2002" NAME="Liang 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Liang TJ, Zhang CQ, Zhang W, Jia XH</AU>
<TI>Effect of Tongxinluo capsule on plasma endothelin and calcitonin gene related peptide in patients with unstable angina pectoris</TI>
<SO>Chinese Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>6</NO>
<PG>435-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2003" NAME="Liu 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Liu J, Zhang LP</AU>
<TI>Clinical observation for Tongxinluo in the treatment of unstable angina pectoris</TI>
<SO>Journal of Medical Theory and Practice</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>7</NO>
<PG>785-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2002a" NAME="Lu 2002a" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lu B</AU>
<TI>Effect of tongxinluo capsule in the treatment of unstable angina</TI>
<SO>Zhejiang Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>9</NO>
<PG>556-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nong-2000" NAME="Nong 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nong MZ, Nong MZ</AU>
<TI>Research on combined treatment of unstable angina pectoris with TCM and WM</TI>
<SO>Zhong Yi Han Shou Tong Xun</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>4</NO>
<PG>51-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nong MZ, Wang J, Wang DB, Can R, Hong M</AU>
<TI>Clinical application of Tongxinlou capsule in unstable angina pectoris</TI>
<SO>Zhe Jiang Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>9</NO>
<PG>516-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nong MZ, Wang J, Wang DB, Can R, Hong M</AU>
<TI>Clinical study on Tongxinluo capsule in treatment for unstable angina pectoris</TI>
<SO>Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care</SO>
<YR>2000</YR>
<VL>7</VL>
<NO>5</NO>
<PG>270-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Song-2002" NAME="Song 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Song B, Xu GX</AU>
<TI>Observation for effects of Tongxinluo in the treatment of unstable angina pectoris</TI>
<SO>Journal of Modern Medicine and Health</SO>
<YR>2002</YR>
<VL>18</VL>
<NO>12</NO>
<PG>1077</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Su-2000" NAME="Su 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Su XY, Hang JX, Zhao ZJ, Zhao L, Hu YL, Su HR</AU>
<TI>Clinical study for Tongxinluo capsule in the treatment of 96 cases of variant angina pectoris</TI>
<SO>Chinese Journal of Integrated Traditional Chinese and Western Critical Care Medicine</SO>
<YR>2000</YR>
<VL>7</VL>
<NO>2</NO>
<PG>119</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2004" NAME="Sun 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun SW, Zhao YX, Liang JL</AU>
<TI>Effect of Tongxinluo capsule on the function of platelet activation in patients with unstable angina pectoris</TI>
<SO>Journal of Difficult and Complicated Cases</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>5</NO>
<PG>260-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xiao-2002" NAME="Xiao 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xiao WL, Dai H, Jiang ZA, Zhang XG, Zhao SJ, Geng XY, Tai WY</AU>
<TI>The effect of protection for endothelial cell of tongxinluo capsule in the treatment of unstable angina</TI>
<SO>Journal of Difficult and Complicated Cases</SO>
<YR>2002</YR>
<VL>1</VL>
<NO>2</NO>
<PG>69-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xiao WL, Dai H, Jiang ZA, Zhang XG, Zhao SJ, Geng XY</AU>
<TI>The influence of tongxinluo capsule for Von Willebrand factor and fibrin conjugated protein of unstable angina (abstract)</TI>
<SO>Chinese Journal of Cardiovascular Diseases</SO>
<YR>2002</YR>
<VL>30</VL>
<NO>5</NO>
<PG>268</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xiao-2004" NAME="Xiao 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xiao YQ, Li WK</AU>
<TI>Effects of tongxinluo in the treatment of unstable angina</TI>
<SO>Acta Medicinae Sinica</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>2</NO>
<PG>152-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2001a" NAME="Yang 2001a" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Yang CR, Li SH</AU>
<TI>Tongxinluo in the treatment of unstable angina 56 cases</TI>
<SO>Luobing theory and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>225-6</PG>
<EN>1</EN>
<ED>Wu YL</ED>
<PB>Chinese Science and Technical Publication House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yao-2003" NAME="Yao 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yao FL</AU>
<TI>Effects of Tongxinluo capsule in the treatment of 30 unstable angina pectoris</TI>
<SO>Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease</SO>
<YR>2003</YR>
<VL>1</VL>
<NO>4</NO>
<PG>244</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2000" NAME="Zhang 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L, Cao W, Wang SZ, Zhou YB, Yang HS</AU>
<TI>A clinical study of tongxinluo capsule in the treatment of unstable angina pectoris</TI>
<SO>Information on Traditional Chinese Medicine</SO>
<YR>2000</YR>
<NO>4</NO>
<PG>29-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2004" NAME="Zhang 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Q, Yang LH, Qiao P, Cui TX</AU>
<TI>Effects of tongxinluo capsule in the treatment of 68 patients with unstable angina pectoris</TI>
<SO>Chinese Journal Of Primary Medicine And Pharmacy</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>9</NO>
<PG>1080-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Gao-2002" NAME="Gao 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gao J, Hui B, Zhang YC, Zhao HL</AU>
<TI>A clinical observation of tongxinluo capsule in the treatment of 60 patients with unstable angina pectoris</TI>
<SO>Journal of Binzhou Medical college</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>2</NO>
<PG>143-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Han-2004b" NAME="Han 2004b" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Han L, Wang LW, Tang JR, Wang XL</AU>
<TI>Effects of tongxinluo capsule in the treatment of 57 patients with unstable angina</TI>
<SO>Journal of Shandong Medicine</SO>
<YR>2004</YR>
<VL>44</VL>
<NO>25</NO>
<PG>52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hu-2001" NAME="Hu 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hu QL, Feng YP</AU>
<TI>Effect of tongxinluo capsule in the treatment of 59 patients with unstable angina pectoris</TI>
<SO>Journal of Helongjiang Traditional Chinese Medicine</SO>
<YR>2001</YR>
<VL>unclear</VL>
<NO>unclear</NO>
<PG>12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2004" NAME="Huang 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang WF, Lu L, Xie GH, Wu LW, Lu J, Chen Y</AU>
<TI>Effects of tongxinluo combined with puerarin in the treatment of unstable angina</TI>
<SO>Modern Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>10</NO>
<PG>1293-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2000" NAME="Li 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Li SL, Luo C</AU>
<TI>Effect analysis of Tongxinluo in the treatment of unstable angina pectoris</TI>
<SO>Anthology of Medicine</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>2</NO>
<PG>208</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2001" NAME="Li 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Li RL</AU>
<TI>A clinical study of tongxinluo capsule in the treatment of unstable angina 34 cases</TI>
<SO>Journal of Emergency Syndromes in Chinese Medicine</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>2</NO>
<PG>107-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2002" NAME="Li 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Li GZ, Zhou YH, Wu LX</AU>
<TI>Influence on thrombase activation and fibrinogen of tongxinluo capsule in the treatment of unstable angina</TI>
<SO>Journal of Handan Senior Medical School</SO>
<YR>2002</YR>
<VL>15</VL>
<NO>2</NO>
<PG>137</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2002b" NAME="Lu 2002b" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lu YN</AU>
<TI>A clinical study of tongxinluo capsule in the treatment of unstable angina pectoris</TI>
<SO>Zhejiang Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>4</NO>
<PG>234-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2004" NAME="Ma 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma LH, Ruan YM, Jiao ZM, Li ZH</AU>
<TI>Effects of chinese herbs for activating blood circulation, removing stasis and supplementing Qi on the circulating endothelial cells in patients with unstable angina pectoris</TI>
<SO>Chinese Journal of Integrative Medicine (English)</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>4</NO>
<PG>267-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qin-2004" NAME="Qin 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qin J, Mai WY</AU>
<TI>Effects of tongxinluo capsule in the treatment of unstable angina pectoris</TI>
<SO>Shenzhen Journal of Integrated Chinese Traditional and Western Medicine</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>1</NO>
<PG>17-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shi-2001" NAME="Shi 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shi YT, Zhang YL, Wei QM, Wang AP</AU>
<TI>A clinical study of tongxinluo combined with low molecular weight heparin in the treatment of unstable angina pectoris</TI>
<SO>China Journal Of Traditional Chinese Medicine And Pharmacy</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>3</NO>
<PG>67-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Su-2001" NAME="Su 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Su GH, Din FS, Huang P</AU>
<TI>Influence on fibrinolytic system of tongxinluo capsule in the treatment of unstable angina</TI>
<SO>Luobing theory of Chinese medicine and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>222-4</PG>
<ED>Wu YL</ED>
<PB>Chinese Science and Technical Publish House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Su-2004" NAME="Su 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Su YG</AU>
<TI>Effects of tongxinluo capsule in the treatment of unstable angina pectoris</TI>
<SO>Shanxi Journal of Chinese Traditional Medicine</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>4</NO>
<PG>27-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2001" NAME="Wang 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Wang YL</AU>
<TI>Observation of tongxinluo capsule in the treatment of unstable angina</TI>
<SO>Luobing theory and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>231</PG>
<ED>Wu Yiling</ED>
<PB>Chinese Science and Technical Publication House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2003a" NAME="Wang 2003a" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wang HJ, Huang YW, Sun J, Zhu CH, Zhang L</AU>
<TI>Effect of Tongxinluo capsule on function of vascular endothelium in patients with unstable angina pectoris</TI>
<SO>Chinese Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>8</NO>
<PG>587-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2003b" NAME="Wang 2003b" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang YH, Ji HX, Li XD</AU>
<TI>Tongxinluo capsule in the treatment of 60 unstable angina pectoris</TI>
<SO>Shanxi Journal of Chinese Traditional Medicine</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>8</NO>
<PG>676-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2003" NAME="Xu 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Xu HH</AU>
<TI>Influence of tongxinluo capsule on Naifold microcirculation in patients with unstable angina pectoris</TI>
<SO>Chinese Journal of Traditional Chinese Basic Medicine</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>3</NO>
<PG>41-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2001b" NAME="Yang 2001b" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Yang K, Wang SQ, Yin B, Li H</AU>
<TI>Effect of tongxinluo in the treatment of unstable angina</TI>
<SO>Luobing theory and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<PG>224</PG>
<EN>1st</EN>
<ED>Wu YL</ED>
<PB>Chinese Science and Technical Publication House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2002" NAME="Yang 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang CJ</AU>
<TI>Lipids level of patients with unstable angina pectoris treating with tongxinluo</TI>
<SO>Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care</SO>
<YR>2002</YR>
<VL>11</VL>
<NO>4</NO>
<PG>238</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan">
<ADDITIONAL_REFERENCES MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan">
<REFERENCE ID="REF-ACC-2001" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="ACC 2001" TYPE="JOURNAL_ARTICLE">
<AU>Cannon CP, Battler A, Brindis RG, Cox JL., Ellis SG, Every NR, Flaherty JT, et al</AU>
<TI>American College of Cardiology Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee)</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2001</YR>
<VL>38</VL>
<NO>7</NO>
<PG>2114-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anon-2002" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Anon 2002" TYPE="OTHER">
<AU>Anon</AU>
<TI>An important new theory on Chinese herbal medicine for treatment of cardio-cerebral vascular diseases</TI>
<SO>China Medical Tribune</SO>
<YR>2002</YR>
<VL>28</VL>
<NO>24</NO>
<PG>16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Braunwald-1989" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Braunwald 1989" TYPE="JOURNAL_ARTICLE">
<AU>Braunwald E</AU>
<TI>Unstable angina: a classification</TI>
<SO>Circulation</SO>
<YR>1989</YR>
<VL>80</VL>
<NO>2</NO>
<PG>410-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Braunwald-1992" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Braunwald 1992" TYPE="BOOK">
<AU>Braunwald E (ed)</AU>
<SO>Heart Disease: A Textbook of Cardiovascular Medicine</SO>
<YR>1992</YR>
<EN>4th</EN>
<PB>Saunders</PB>
<CY>Philadelphia/ London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Braunwald-1994" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Braunwald 1994" TYPE="BOOK">
<AU>Braunwald E, Mark DB, Jones RH, et al</AU>
<SO>Unstable angina: Diagnosis and management.Clinical Practice Guideline Number 10. AHCPR Publication No. 94-0602</SO>
<YR>1994</YR>
<PB>Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, U.S. Department of Health and Human Services</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CCS-1972" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="CCS 1972" TYPE="JOURNAL_ARTICLE">
<AU>Campeau L</AU>
<TI>Grading scale for classification of severity of angina</TI>
<SO>Circulation</SO>
<YR>1976</YR>
<VL>54</VL>
<NO>3</NO>
<PG>522-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-1985" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Chen 1985" TYPE="JOURNAL_ARTICLE">
<AU>Chen CY</AU>
<TI>Effect of Scolopendra extract in experiment on rabbit heart</TI>
<SO>Chinese Medicine Pharmacology and Clinical Practice</SO>
<YR>1985</YR>
<VL>1</VL>
<NO>1</NO>
<PG>124-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deng-1991" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Deng 1991" TYPE="JOURNAL_ARTICLE">
<AU>Deng CQ</AU>
<TI>Effect of Radix Paeoniae Rubra water-extraction in the experiment of anticoagulation</TI>
<SO>Chinese Medicine Pharmacology and Clinical Practice</SO>
<YR>1991</YR>
<VL>7</VL>
<NO>1</NO>
<PG>20-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fulder-1996" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Fulder 1996" TYPE="BOOK">
<AU>Fulder S</AU>
<SO>The Handbook of Alternative and Complementary Medicine</SO>
<YR>1996</YR>
<EN>3rd</EN>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gu-1983" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Gu 1983" TYPE="JOURNAL_ARTICLE">
<AU>Gu XL, Xu LS</AU>
<TI>The effect of myocardial kinetics of dog in the experimental of Ginseng, Radix Aconiti Lateralis Preparata and their complex</TI>
<SO>Journal of Emergency in Traditional Chinese Medicine</SO>
<YR>1983</YR>
<VL>3</VL>
<NO>1</NO>
<PG>39-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICSI-2005a" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="ICSI 2005a" TYPE="OTHER">
<AU>Institute for Clinical Systems Improvement (ICSI)</AU>
<TI>Diagnosis and treatment of chest pain and acute coronary syndrome (ACS)</TI>
<SO>Summary available at http://www.guideline.gov/summary/summary.aspx?view_id=1&amp;doc_id=6230&amp;nbr=4001. Accessed 12th Sept. 2005</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICSI-2005b" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="ICSI 2005b" TYPE="OTHER">
<AU>Institute for Clinical Systems Improvement (ICSI)</AU>
<TI>Diagnosis and treatment of chest pain and acute coronary syndrome (ACS).</TI>
<SO>Summary available at http://www.guideline.gov/summary/summary.aspx?doc_id=8362&amp;nbr=4683 . Accessed 10th Aug. 2006</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jin-1983" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Jin 1983" TYPE="JOURNAL_ARTICLE">
<AU>Jin RM, Mao P, Yu YM, Li YK, Wang JM</AU>
<TI>Comparison of pharmacological action of Radix Ginseng Rubra with freeze-dried Ginseng, and Ginseng dried in the sun</TI>
<SO>Journal of Chinese Medicine</SO>
<YR>1983</YR>
<VL>8</VL>
<NO>1</NO>
<PG>34-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juni-2001" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Juni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Juni P, Altman DG, Egger M</AU>
<TI>Assessing the quality of controlled clinical trials</TI>
<SO>British Medical Journal</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-KAU-1996" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="KAU 1996" TYPE="OTHER">
<AU>KAU (AHCPR guidelines abbreviated 1/96)</AU>
<TI>Unstable Angina: Diagnosis and Management</TI>
<SO>http://www.medana.unibas.ch/eng/internt/angina.htm. Accessed at 20th Feb 2005</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Li-1989" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Li 1989" TYPE="JOURNAL_ARTICLE">
<AU>Li F, Yuan ZQ, He XY, Zhao YG, Chen GL</AU>
<TI>A study of thrombolytic function of Hirudin</TI>
<SO>Tianjin Journal of Traditional Chinese Medicine</SO>
<YR>1989</YR>
<VL>7</VL>
<NO>3</NO>
<PG>27-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liu-1997" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Liu 1997" TYPE="JOURNAL_ARTICLE">
<AU>Liu JX, Shang XH, Wang G, Zhang SC, Gao XD</AU>
<TI>Effect of Tongxinluo capsule on experimental myocardial ischemia, arrhythmia and hyperlipidemia</TI>
<SO>Chinese Journal of Integrated Traditional and Western Medicine</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>7</NO>
<PG>425-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liu-2000" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Liu 2000" TYPE="COCHRANE_REVIEW">
<AU>Liu JP, McIntosh H, Lin H</AU>
<TI>Chinese medicinal herbs for chronic hepatitis B</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nong-1989" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Nong 1989" TYPE="JOURNAL_ARTICLE">
<AU>Nong ZJ, Shen YY, Dong HC</AU>
<TI>The effect of Eupolyphaga Sinensis Walk alkaloids on rabbits cardial pump function</TI>
<SO>Journal of Anhui Traditional Chinese Medical College</SO>
<YR>1989</YR>
<VL>8</VL>
<NO>3</NO>
<PG>84-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nu-1983" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Nu 1983" TYPE="JOURNAL_ARTICLE">
<AU>Nu EW, Zhao DZ, Wang R, Wang ML, Zhou X</AU>
<TI>Effect of Radix Paeoniae Rubrasin in experiment on hyperlipemia and hypercholesterolemia mice</TI>
<SO>Journal of Integrated Traditional and Western Medicine</SO>
<YR>1983</YR>
<VL>3</VL>
<NO>2</NO>
<PG>109-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ou-1987" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Ou 1987" TYPE="JOURNAL_ARTICLE">
<AU>Ou XC, Ding JX, Zhang N</AU>
<TI>Experimental survey of 126 Chinese medicine antithrombin function</TI>
<SO>Chinese Traditional and Herbal Drugs</SO>
<YR>1987</YR>
<VL>18</VL>
<NO>4</NO>
<PG>21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pei-1986" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Pei 1986" TYPE="JOURNAL_ARTICLE">
<AU>Pei YQ, Wen SR, Wang XY, Huo SP, Wei MC</AU>
<TI>Study of cardiac stimulation of Ginsenoside of upper part over grand</TI>
<SO>Journal of Beijing Medical University</SO>
<YR>1986</YR>
<VL>18</VL>
<NO>2</NO>
<PG>140-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shang-1997" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Shang 1997" TYPE="JOURNAL_ARTICLE">
<AU>Shang Xiaohong, Wang Gang, Liu Jianxun, Zhang Shucai, Gao Xuedong</AU>
<TI>Effect of Tongxinluo capsule on hemodynamics and myocardial oxygen consumption in dogs</TI>
<SO>Chinese Journal of Integrated Traditional and Western Medicine</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>8</NO>
<PG>487-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-1980" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Wang 1980" TYPE="JOURNAL_ARTICLE">
<AU>Wang YY, Zhou JL, Wu PJ, Zhao MX</AU>
<TI>Pharmacological action of Radix Paeoniae Rubra extraction for injection</TI>
<SO>Journal of Chinese Medicinal Materials Research</SO>
<YR>1980</YR>
<NO>1</NO>
<PG>31-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-1998" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Wang 1998" TYPE="BOOK">
<AU>Wang YS, Deng WL, Xue CS</AU>
<SO>Pharmacology and applications of Chinese Materia Medica</SO>
<YR>1998</YR>
<EN>2nd</EN>
<PB>People's Health Publishing House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-1994" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Wu 1994" TYPE="JOURNAL_ARTICLE">
<AU>Wu JB, Liu HB, Lu WH, Lu YW, Wang Q</AU>
<TI>Comparison of adjustment function of three Hirudo products</TI>
<SO>Chinese Journal of Traditional Medicine</SO>
<YR>1994</YR>
<VL>19</VL>
<NO>6</NO>
<PG>343-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-1998" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Wu 1998" TYPE="OTHER">
<AU>Wu YL</AU>
<TI>Method of making tongxinluo capsule treating coronary artery disease and angina</TI>
<SO>Chinese patents.Application number 97104187. Announcement number 1198332. Available at http://210.73.128.12/luzhanming/files/sz1.htm. Accessed 12 Sept. 2005</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-2001a" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Wu 2001a" TYPE="BOOK">
<AU>Wu YL</AU>
<SO>Luobing theory of Chinese medicine and cardio-cerebral angiopathy</SO>
<YR>2001</YR>
<EN>1st</EN>
<PB>Chinese Science and Technical Publish House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-2001b" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Wu 2001b" TYPE="JOURNAL_ARTICLE">
<AU>The collaborative study group on trends of cardiovascular diseases in China</AU>
<TI>Current status of major cardiovascular risk factors in Chinese populations and their trends in the past two decades</TI>
<SO>Chinese Journal of Cardiology</SO>
<YR>2001</YR>
<VL>29</VL>
<NO>2</NO>
<PG>74-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xu-1988a" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Xu 1988a" TYPE="JOURNAL_ARTICLE">
<AU>Xu YJ</AU>
<TI>Effect of inhibition platelet adhesion reaction of Radix Ginseng</TI>
<SO>Journal of Pharmacology</SO>
<YR>1988</YR>
<VL>23</VL>
<NO>5</NO>
<PG>284-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xu-1988b" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Xu 1988b" TYPE="JOURNAL_ARTICLE">
<AU>Xu JJ, Huang JM, Chen XH, Mong QD</AU>
<TI>Affect of Hirudo water-extraction on mice and human platelet adhesion reaction and blood rheology</TI>
<SO>Chinese Traditional Medicine Pharmacology and Clinical Practice</SO>
<YR>1988</YR>
<VL>4</VL>
<NO>4</NO>
<PG>35-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yang-1989" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Yang 1989" TYPE="JOURNAL_ARTICLE">
<AU>Yang YF, Wang MM, Wang MH, Su XL, Yu ZQ</AU>
<TI>The effect of Eupolyphaga Sinensis Walk alkaloids on animal tolerance of hypoxia</TI>
<SO>Chinese Traditional Herbal Drags</SO>
<YR>1989</YR>
<VL>20</VL>
<NO>6</NO>
<PG>260-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yuan-1983" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Yuan 1983" TYPE="JOURNAL_ARTICLE">
<AU>Yuan WX, Gui LH, Zhou JY, Li YY, Yu QH</AU>
<TI>Pharmacological action of Radix Ginsenoside</TI>
<SO>Journal of Chinese Pharmacology</SO>
<YR>1983</YR>
<VL>4</VL>
<NO>2</NO>
<PG>124-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-1978" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Zhang 1978" TYPE="JOURNAL_ARTICLE">
<AU>Zhang ZY, Lang BP, Tao ZN, Li ZH, Li F</AU>
<TI>Study of anti-angina action of Hirudo extract</TI>
<SO>Journal of Tianjin Medicine</SO>
<YR>1978</YR>
<NO>3</NO>
<PG>342-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-1990" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Zhang 1990" TYPE="JOURNAL_ARTICLE">
<AU>Zhang YZ, Yan XY, Zhang YR, Wei TX, Dang YH, Peng SL</AU>
<TI>The effect of Radix Paeoniae Rubra in the experiment of chronic hyperlipemia rabbits' plasma TXB2 and PGF1alpha</TI>
<SO>Journal of Integrated Traditional and Western Medicine</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>11</NO>
<PG>669-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zheng-1998" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Zheng 1998" TYPE="BOOK_SECTION">
<AU>Zheng HZ, Dong ZH, Se J</AU>
<TI>Periostracum Cicadae</TI>
<SO>Modern Study of Traditional Chinese Medicine</SO>
<YR>1998</YR>
<PG>5137-45</PG>
<EN>1st</EN>
<PB>Xue Yuan Press</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Chang-2004">
<CHAR_METHODS>
<P>DESIGN: Randomised allocation was mentioned<BR/>RANDOMISATION PROCEDURE: unclear.<BR/>BLINDING: No mention<BR/>DURATION: 6 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>All participants were outpatients.<BR/>68 participants (age 65+/-4 years) in tongxinluo group included 38 with de novo effort angina, 14 with worsening effort angina and 16 with spontaneous angina; 46 in control group (age 64+/-6 years) included 20 with de novo effort angina, 10 with worsening effort angina and 16 with spontaneous angina.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Routine treatment in both groups included isosorbide mononitrate, beta blockers, aspirin and calcium antagonist. Tongxinluo capsule were added to intervention group with a dose of three pills, tid. Length of treatment: 6 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Angina symptom marked improvement: 25/68 in tonxinluo group and 20/46 in control group;<BR/>2. Electrocardiogram (ECG) marked improvement: 30/68 in tongxinluo group and 20/46 in control group.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Hebei Tangshan City Hospital</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cheng-2002">
<CHAR_METHODS>
<P>DESIGN: randomised controlled trial.<BR/>RANDOMISATION PROCEDURE: unclear.<BR/>BLINDING: not used.<BR/>UNIT OF COMPARISON: individuals.<BR/>DURATION: 4 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Did not say whether participants were inpatients or outpaitents.<BR/>32 patients were randomly allocated to tongxinluo capsule group and 31 to control. No detailed description for baseline characteristics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intervention group: tongxinluo capsule 3 pills, tid; control group Isosorbide mononitrate 10mg, tid, and aspirin 100mg/day. Length of treatment: 4 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Angina symptom marked improvement: tongxinluo group 62.49%; control group 43.58%; improvement: tongxinluo group 31.3%; control group 24.70%; no improvement: tongxinluo group 6.21%, control group 31.72%;<BR/>2. Frequency of angina attacks: tongxinluo group 1.32+/-0.31 times; control group 6.73+/-0.32 times.<BR/>3. Nitroglycerin consumption: tongxinluo group 0.19+/-0.1mg/d; control group 1.12+/-0.43mg/d.<BR/>4. Electrocardiogram (ECG) marked improvement: tongxinluo group 54.23%; control group 32.17%; improvement: tongxinluo group 23.32%; control group 26.57%; no improvement: tongxinluo group 22.45%, control group 58.74%.<BR/>5. No side effects were observed.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Shandong University Hospital, China.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Han-2004a">
<CHAR_METHODS>
<P>DESIGN: randomised controlled trial.<BR/>RANDOMISATION PROCEDURE: unclear.<BR/>BLINDING: not used.<BR/>UNIT OF COMPARISON: individuals.<BR/>DURATION: 4 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Did not say whether were inpatients or outpatients.<BR/>30 participants in tongxinluo capsule group, 16 male, 14 female, age 45-70 (mean age 59+/-10), angina for 1.0-4.8 (mean 2.4) years;<BR/>30 in isosorbide mononitrate group, 17 male, 13 female, age 49-69 (mean age 61+/-9), course of angina 1.2-4.4 (mean 2.3) years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Basic treatment by aspirin in both groups. Additional to this, tongxinluo capsule 4 pills, tid, in intervention group; isosorbide mononitrate 20mg, bid in control group. Length of treatment: 4 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Frequency of angina attack: tongxinluo group: 3.2+/-0.5, control group: 2.9+/0.6;<BR/>2. Duration of angina: tongxinluo group: 2.4+/-0.4; control group: 2.1+/-0.2;<BR/>3. Nitric oxide (NO) level: tongxinluo group: 28.9+/-2.1umol; control group: 26.7+/-2.4 umol;<BR/>4. Endothelin (ET) level: tongxinluo group: 45+/-7ng/L; control group: 47+/-7 ng/L.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Shandong Jinan City Licheng hospital.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jia-1999">
<CHAR_METHODS>
<P>DESIGN: randomised controlled trial.<BR/>RANDOMISATION PROCEDURE: unclear.<BR/>BLINDING: not used.<BR/>UNIT OF COMPARISON: individuals.<BR/>DURATION: 4 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Both inpatients and outpatients included.<BR/>30 patients in tongxinluo capsule group, male 19 female 11, age 37-68, (mean 55.46+/-6.92) years, duration of angina 4-12 years (mean 7.58+/-1.72), body mass index 24.94+/-3.41; <BR/>31 in isosorbide mononitrate group, 18 male 13 female, age 40-67 (mean 54.83+/-6.87) years, duration of angina 3.8-9.0 (mean 6.86+/-1.38) years, body mass index 24.79+/-2.61. <BR/>Patients with more than one of following conditions were excluded: AMI in last 6 months, pregnancy and feeding woman, liver and renal function insufficiency, combined with hypertension, psychotic, hypersensitive for tongxinluo capsule.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tongxinluo group: 2 pills, tid; Control group: isosorbide mononitrate 20mg, twice a day. <BR/>Length of treatment: 4 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Symptom improvement: marked improvement tongxinluo group 17/30, control group 19/31; improvement: tongxinluo group 9/30, control group 8/31; no improvement: tongxinluo group 4/30, control group 4/31.<BR/>2. Electrocardiogram (ECG) marked improvement: tongxinluo group 16/30, control group 12/31; improvement: tongxinluo group 7/30, control group 11/31; no improvement or worse: tongxinluo group 7/30, control group 8/30.<BR/>3. Nitricoxide (NO) level (umol/L): after treatment: tongxinluo group 30.78+/-3.94, control group 32.02+/-3.68;<BR/>4. Endothelin (ET) level (ng/L): after treatment: tongxinluo group: 48.24+/-7.54, control group 49.63+/-7.86</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Beijing Youyi Hospital</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jia-2001">
<CHAR_METHODS>
<P>DESIGN: randomised controlled trial.<BR/>RANDOMISATION PROCEDURE: unclear.<BR/>BLINDING: not used.<BR/>UNIT OF COMPARISON: individuals.<BR/>DURATION: 4 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Total number: 72<BR/>Tongxinluo group: 37, angina for 3-10 years;<BR/>Control group: 35, angina for 3.5-10 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Routine treatment with Isosorbide mononitrate or hexinshuang (herbal medicine), aspirin, beta blockers were used in both groups. Tongxinluo capsule added to treatment group, 4 pills, tid. <BR/>Length of treatment: 4 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Symptom improvement (frequency of angina attack): marked improvement: tongxinluo group 19/37, control group 16/35; improvement: tongxinluo group 12/37, control group 11/35, no effect tongxinluo group 6/37, 8/35;<BR/>2. Electrocardiogram (ECG) improvement: <BR/>3. Blood pressure;<BR/>4. Heart rate;<BR/>5. TG, TC, HDL-C<BR/>6. Blood viscosity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The First Hospital of Chinese University of Medicine</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Liang-2002">
<CHAR_METHODS>
<P>DESIGN: randomised controlled trial.<BR/>RANDOMISATION PROCEDURE: unclear.<BR/>BLINDING: not used.<BR/>UNIT OF COMPARISON: individuals.<BR/>DURATION: 4 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>90 inpatients and outpatients. <BR/>Tongxinluo group 60, age 41-66 years, 41 male 19 female, duration of angina 5-20 (mean 10.8+/-3.7) years, angina severity category: degree i 9 cases, degree ii 25 cases, degree iii 19 cases, degree iv 7 cases.<BR/>Control group: 30, age 45-66 years, male 20, female 10, duration of angina 4-22 (mean 11.2+/-4.1) years, severity of angina: degree i 5 cases, degree ii 12 cases, degree iii 10 cases, degree iv 3 cases.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Basic treatment included Isosorbide mononitrate and aspirin in both groups.<BR/>Tongxinluo group: tongxinluo capsule 4 pills, tid, danshen group: danshen tablet 4 pills, t.i.d. <BR/>Length of treatment: 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Endotheliosin (ET)(ng/L): tongxinluo group: 44.36+/-10.51; control group: 49.62+/-11.75<BR/>2. Calciton gene relative peptide (CGRP)(ng/L): tongxinluo group: 49.02+/-9.23; control group: 45.02+/-8.12</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Shandong Province Hospital.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Liu-2003">
<CHAR_METHODS>
<P>DESIGN: randomised controlled trial.<BR/>RANDOMISATION PROCEDURE: unclear.<BR/>BLINDING: not used.<BR/>UNIT OF COMPARISON: individuals.<BR/>DURATION: 2 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Total number of 90 inpatients:<BR/>tongxinluo group: 60, male 32, average age 52.8 years.<BR/>Control group: 30, male 17, average age 53.5 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Basic treatment included beta blockers, nitrates, isosorbide mononitrate in both groups.<BR/>In addition to these, tongxinluo capsule was used in intervention group with 4 pills, tid. Length of treatment: 2 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Marked improvement: tongxinluo group 48/60, control group 14/30;<BR/>2. Improvement: tongxinluo group 11/60, control group 12/30;<BR/>3. No improvement: tongxinluo group 1/60, control group 4/30.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The Third Hospital of Yanzhou Mineral Industry Group, Shandong, CHINA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lu-2002a">
<CHAR_METHODS>
<P>DESIGN: randomised controlled trial.<BR/>RANDOMISATION PROCEDURE: unclear.<BR/>BLINDING: not used.<BR/>UNIT OF COMPARISON: individuals.<BR/>DURATION: 2 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Total 57 inpatients: <BR/>tongxinluo group 30 (male 21, female 9); <BR/>control group 27, (male 19, female 8).<BR/>People with unstable angina who also had AMI, post AMI or contraindications to anticoagulation treatment were excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Low molecular weight molecular heparin + Aspirin with tongxinluo 4 pills, tid;<BR/>2. Low weight molecular weight heparin + Aspirin.<BR/>Length of treatment: 2 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Marked improvement: cessation of angina attacks or 2 times/wk, physical activity tolerance improved, ECG recovered or ST-T segment obviously improved;<BR/>2. General improvement: frequency of angina attack reduced to less than 50%, or time of angina reduced, ST improved;<BR/>3. No effect: symptoms no improve or AMI, sudden death.<BR/>4. Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ShangRao City Hospital, CHINA.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nong-2000">
<CHAR_METHODS>
<P>DESIGN: randomised controlled trial. <BR/>RANDOMISATION PROCEDURE: unclear.<BR/>BLINDING: not used.<BR/>Variable duration with evaluations done at day 1, day 2 and day 3.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>46 participants, did not say whether patricipants were inpatients or outpatients.<BR/>23 patients in tongxinluo group, and 23 patients to routine treatment group. <BR/>No detailed description for comparing of baseline.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tongxinluo (3-4 pills tid) with routine therapy; routine therapy only in control group.<BR/>Routine therapy include aspirin, beta II/alpha III receptor antagonists, heparin, nitrites, beta receptor blocking agent, calcium antagonist. <BR/>Length of treatment: drugs were taken until cTnT was back to normal.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Serum cardiac troponin T (cTnT) (data unusable);<BR/>2. Creatinine kinase (CK);<BR/>3. Isoenzyme MB (CK-MB): there was no any positive finding and no information in detail;<BR/>4. LDH: no any positive finding and no information in detail;<BR/>5. ALT: no any positive finding and no information in detail;<BR/>6. Consumption of nitroglycerin: tongxinluo group 3+/-1 pills, control group 4+/1 pills;<BR/>7. Angina scores (=ST reduce value (mV) * angina time): tongxinluo group 2.72+/1.85, control group 3.76+/-2.55;<BR/>8. Cardiac vascular events (AMI, sudden death, PTCA or CABG): tongxinluo group 4/23, control group 5/23.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The Second Hospital of Nanjing Medical University, China.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Song-2002">
<CHAR_METHODS>
<P>DESIGN: randomised controlled trial.<BR/>RANDOMISATION PROCEDURE: unclear.<BR/>BLINDING: not used.<BR/>UNIT OF COMPARISON: individuals.<BR/>DURATION: 10 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>60 inpatients all with ST-T dynamic change.<BR/>Tongxinluo group 30, male 18, female 12, age 62.1+/-5.8 years<BR/>Control group 30 male 22, female 8, age 58.9+/-5.1 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Nitroglycerin and low molecular weight heparin as basic treatment in both groups<BR/>Added to this the intervention group used tongxinluo capsule 4 pills, tid.<BR/>Beta blockers and calcium antagonists were used depending on the patients' status. <BR/>Length of treatment: 10 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Frequency of angina attack;<BR/>2. Length of angina attack;<BR/>3. Dynamic ST-T segment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>BingNan Hospital, Bing Zhou City, Shandong, CHINA.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Su-2000">
<CHAR_METHODS>
<P>DESIGN: quasi-randomised controlled trial.<BR/>BLINDING: not used.<BR/>DURATION: 15 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>192 outpatients.<BR/>Male 120, female 72. Age 25-86; 40 patients with hypertension, 50 with diabetes, 74 with no other disease. <BR/>96 patients in each group and with similar baseline on age, duration of angina and concomitant diseases.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Routine treatment: nitrates and calcium antagonist.<BR/>Group A: tongxinluo capsule (3 pills each time, 3 times a day) with routine treatment.<BR/>Group B: routine treatment. <BR/>Length of treatment: 15 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Marked improvement: symptom disappeared, ECG restored: tongxinluo group 50/96, control group 44/96.<BR/>2. General improvement: symptom improved but slight angina occasionally occur, ECG improved: tongxinluo group 38/96, control group 28/96.<BR/>3. No improvement: tongxinluo group 8/96, control group 24/96.<BR/>4. AMI events: tongxinluo group 2/96, control group 12/96.<BR/>5. ECG improvement: tongxinluo group 40/96, control group 28/96.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Changzhou city hospital, Hebei province, China.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sun-2004">
<CHAR_METHODS>
<P>DESIGN: randomised controlled trial.<BR/>RANDOMISATION PROCEDURE: unclear.<BR/>BLINDING: not used.<BR/>UNIT OF COMPARISON: individuals.<BR/>DURATION: 8 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>46 inpatients.<BR/>23 in tongxinluo group, male 18, female 5, age 43-70 (mean 50+/-6) years, angina for 2.2-12.5 (mean 6.8+/-5.2) years. 23 in control group, male 15 female 8, age 48-71 (mean 52+/-6) years, angina for 2.1-12.5 (mean 7.2+/-6.2) years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Routine treatment included aspirin and nitrates.<BR/>Added to these, tongxinluo capsules 3 pills was used in intervention group, but no information is given on dosage. <BR/>Length of treatment: 8 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Marked improvement: tongxinluo group: 8/23, control group: 5/23;<BR/>2. Improvement: tongxinluo group: 12/23, control group 10/23;<BR/>3. No effect: tongxinluo group 3/23, control group 8/23;<BR/>4. ECG marked improvement: tongxinluo group 8/23, control group 4/23; improvement: tongxinluo group 9/23, control group 7/23; no effect: tongxinluo group 6/23, control group 12/23;<BR/>4. Platelet activation marker selectin p (CD62P): tongxinluo group 5.961.44; control group 16. 863.91;<BR/>5.Platelet activation marker CD63: tongxinluo group 3.590.86; control group 8. 673.09.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Shandong University, Qilu Hospital, China.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Xiao-2002">
<CHAR_METHODS>
<P>DESIGN: randomised controlled trial.<BR/>RANDOMISATION PROCEDURE: unclear.<BR/>BLINDING: not used.<BR/>UNIT OF COMPARISON: individuals.<BR/>DURATION: 4 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Total number of 30 inpatients.<BR/>15 in tongxinluo group with average age 57.2+/- 11.3 years, 15 in control group with average age 58.3 +/- 9.6 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Basic treatment include Isosorbide mononitrate 10mg, tid; Hexinshuang 30mg, tid; beta blockers 12.5mg, bid; aspirin 25mg, bid in both groups. <BR/>Added to these, tongxinluo capsule was used in the intervention group, 4 pills, t.i.d. <BR/>Length of treatment: 4 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Symptom improvement: marked improvement 8/15 in tongxinluo group and 5/15 in control group; improvement: 4/15 in tongxinluo group and 5 in control group; no effect: 2 in tongxinluo group and 3 in control group; worse: 1 in tongxinluo group and 2 in control group.<BR/>2. von Willebrand factor (vWF)(%): tongxinluo group before treatment 162.3+/-25.4, after treatment 118.7+/-27.3; control group: before treatment 156.7+/-28.2, after treatment 141.3+/-36.1;<BR/>3. Fibronectin (Fn) (mg/dl): tongxinluo group before treatment 43.8+/-7.1, after treatment 34.2+/6.7; control group before treatment 45.2+/-6.6, after treatment 43.8+/-4.1.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The Third Hospital of Hebei Medical University.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Xiao-2004">
<CHAR_METHODS>
<P>DESIGN: randomised controlled trial.<BR/>RANDOMISATION PROCEDURE: unclear.<BR/>BLINDING: not used.<BR/>UNIT OF COMPARISON: individuals.<BR/>DURATION: 3 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>160 inpatients.<BR/>Tongxinluo group: 80, male 54, female 26, mean age 55.46+/-6.92 years, angina for 7.58+/- 1.72 years <BR/>Isosorbide (Nunanxinkang) group: group: 80, 49 male, 31 female, mean age 54.83+/-6.78 years, angina for 6.98+/-1.38 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Basic treatment included aspirin 150mg, beta blockers 12.5mg-25mg in both groups. <BR/>Tongxinluo group additionally received 3 tongxinluo capsules tid, and control group received isosorbide mononitrate 20mg, twice a day.<BR/>Length of treatment: 3 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Symptom improvement: marked improvement: tongxinluo group 46/80, isosorbide mononitrate group 43/80; improvement: tongxinluo group 24/80, isosorbide mononitrate group 25/80; no improvement: tongxinluo gorup 10/80, isosorbide mononitrate group 12/80.<BR/>2. Frequency of angina attack: tongxinluo group 3.96+/-0.62, isosorbide mononitrate group 5.12+/-0.72;<BR/>3. ECG improvement: market improvement: tongxinluo group 43/80, isosorbide mononitrate 36/80; improvement: tongxinluo group 24/80, isosorbide mononitrate group 19/80; no improvement and worse: tongxinluo group 12/80, isosorbide mononitrate group 25/80.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The Third Hospital of Nanning City, Guangxi, CHINA.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yang-2001a">
<CHAR_METHODS>
<P>DESIGN: randomised controlled trial.<BR/>RANDOMISATION PROCEDURE: unclear.<BR/>BLINDING: not used.<BR/>UNIT OF COMPARISON: individuals.<BR/>DURATION: 4 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Total number of 108 participants (no desciption for inpatients or outpatients).<BR/>Tongxinluo group: 56 with age 42~88 years and angina for 1~2 years, male 32, female 24.<BR/>Control group: 52 with the age 40~84 years and angina for 1~9 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Tongxinluo group: 4 pills, tid.<BR/>2. Control group: beta blockers 50mg, bid, aspirin 50mg, daily, Isosorbide mononitrate 10mg, tid, Dikeli 0.25gms per day. <BR/>Length of treatment: 4 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Symptom improvement: Marked improvement: tongxinluo group 33/56, control group 25/52; improvement: tongxinluo group 21/56, control group 18/52; no improvement tongxinluo group 2/56, control group 9/52;<BR/>2. ECG improvement: marked improvement: tongxinluo group 31/56, control group 20/52; improvement: tongxinluo group 19/56, control group 21/56; no improvement tongxinluo group 6/56, control group 11/52.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nongdu Hospital, Zhongshan City, Guangdong, CHINA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yao-2003">
<CHAR_METHODS>
<P>DESIGN: randomised controlled trial.<BR/>RANDOMISATION PROCEDURE: unclear.<BR/>BLINDING: not used.<BR/>UNIT OF COMPARISON: individuals.<BR/>DURATION: 4 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Each group included 15 inpatients with UA.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Routine treatment in both groups include isosorbide mononitrate, beta blockers, aspirin and captopril. <BR/>Tongxinluo capsule was given in addition to intervention group with a dose of three pills, tid. <BR/>Length of treatment: 4 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Marked improvement of symptom: tonxinluo group 8/15, control group 7/15; improvement: tongxinluo group 6/15, control group 5/15, no effect: tongxinluo group 1/15, control group 3/15.<BR/>2. No side effect were found.<BR/>3. Total cholesterol (Tch), triglyceride (TG), high density lipoprotein cholesterol (HDL-c), low density lipoprotein cholesterol (LDL-c), data unusable.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Shanxi Taiyuan, Yinze Skeleton Disease Hospital.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zhang-2000">
<CHAR_METHODS>
<P>Randomised allacation was mentioned, but the method of randomisation unclear. <BR/>No mention of blinding.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>66 inpatients.<BR/>Tongxinluo group: 36 ( male 27, female 9), age 39-62 (mean 54.3) years; 10 with effort angina, 8 with spontaneous angina, 18 with mixed angina; <BR/>Control group 30 (male 23, female 7) age 40-60 (mean 52.5) years; 7 with effort angina, 7 spontaneous angina, 16 mixed angina.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Routine treatment in both groups include isosorbide mononitrate, beta blockers, aspirin and calcium antagonist. <BR/>Tongxinluo capsule was additional given to the intervention group with a dose of four pills, tid. <BR/>Length of treatment: 4 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Improvement of symptoms:<BR/>(1) Number of improvement on angina attack tongxinluo group 35/36, control group 24/30;<BR/>(2) Improvement on other symptoms: tongxinluo group 32/36; control group 20/30;<BR/>(3) Improvement on ECG: tongxinluo group 29/36, control group 16/30;<BR/>(3) Improvement on total effect: tongxinluo group 32/36, control group 20/30;<BR/>2. Withdraw or reduce for nitroglycerin: withdraw: tongxinluo group 24/36, control group 11/30; reducing to half: tongxinluo group 11/36, control group 14/30.<BR/>3. No adverse effect was observed.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Heilongjiang Medical University, the Second Hospital, and Heilongjiang Traditional Chinese Medical University.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zhang-2004">
<CHAR_METHODS>
<P>DESIGN: randomised controlled trial.<BR/>RANDOMISATION PROCEDURE: unclear.<BR/>BLINDING: not used.<BR/>UNIT OF COMPARISON: individuals.<BR/>DURATION: 4 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>68 inpatients and outpatients were included. <BR/>33 in tongxinluo group (23 male, 10 female), with average ages 57.46.9 years, and 35 in control group (22 male 13 female) with average ages 58.37.4 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Intervention group: tongxinluo capsule 2 pills, tid;<BR/>2. Control group: Isosorbide mononitrate 20mg, bid. During the treatment, did not use calcium antagonist, beta blockers and nitrates.<BR/>Length of treatment: 4 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Marked improvement: tongxinluo group 19/33, control group 22/35;<BR/>2. Improvement: tongxinluo group 10/33, control group 9/35;<BR/>3. No improvement: tongxinluo group 4/33, control group 4/35.<BR/>4. Frequency of angina attack: tongxinluo group 3.850.51; control group 4.770.53;<BR/>5. ECG marked improvement: tongxinluo group 18/33, control group 15/35; improvement: tongxinluo group 8/33, control group 12/35; no improvement and worse: tongxinluo group 7/33, control group 8/35.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Henan Zhengzhou university hospital.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>tid=thee times per day<BR/>bid=twice per day</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Gao-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Seven post AMI patients were included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Han-2004b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data unusable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hu-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised controlled study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Huang-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Included eight patients with post AMI.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Li-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Twenty three post AMI patients were included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Li-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Included post AMI patients in both two groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Li-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcomes did not match the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lu-2002b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised controlled study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ma-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcomes did not match the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Qin-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shi-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised controlled study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Su-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcomes did not match the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Su-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Seventeen post AMI patients were included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data unusable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-2003a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Twelve post AMI patients were included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-2003b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Fourteen post AMI patients were included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Xu-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised-controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yang-2001b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ten post AMI patients were included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yang-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcomes did not match the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chang-2004">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cheng-2002">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Han-2004a">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jia-1999">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jia-2001">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Liang-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Liu-2003">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lu-2002a">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nong-2000">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Song-2002">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Su-2000">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sun-2004">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Xiao-2002">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Xiao-2004">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Yang-2001a">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Yao-2003">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2000">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2004">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-09-09 10:50:37 +0100" MODIFIED_BY="Karen Hovhannisyan" NO="1">
<TITLE>Composition of Tongxinluo</TITLE>
<TABLE COLS="4" ROWS="9">
<TR>
<TH>
<P>Latin name</P>
</TH>
<TH>
<P>Common name</P>
</TH>
<TH>
<P>Pharma. actions</P>
</TH>
<TH>
<P>Dosage proportion</P>
</TH>
</TR>
<TR>
<TD>
<P>Radix ginseng</P>
</TD>
<TD>
<P>Ren shen</P>
</TD>
<TD>
<P>strengthens cardiac contractility, increasing cardiac output, and has cardiokinetic function, slows heart rate down, dilates blood vessel, anticoagulation, inhibits platelet adhesion reaction</P>
</TD>
<TD>
<P>10% to 20%</P>
</TD>
</TR>
<TR>
<TD>
<P>Scorpio</P>
</TD>
<TD>
<P>Scorpion</P>
</TD>
<TD>
<P>treatment of hypertension, apoplexy, arteriosclerosis, some nervous system diseases, various tumefaction and infections</P>
</TD>
<TD>
<P>10% to 20%</P>
</TD>
</TR>
<TR>
<TD>
<P>Hirudo</P>
</TD>
<TD>
<P>Leech</P>
</TD>
<TD>
<P>anticoagulation, thrombolysis, reduces viscosity of whole blood, reduces ischaemia, induces cholesterol and anti-atherosclerosis</P>
</TD>
<TD>
<P>20% to 30%</P>
</TD>
</TR>
<TR>
<TD>
<P>Eupolyphaga seu steleophage</P>
</TD>
<TD>
<P>Eupolyphaga sinensis walk, Ground beetle</P>
</TD>
<TD>
<P>increase cardiac output, improve tolerance of hypoxia</P>
</TD>
<TD>
<P>10% to 20%</P>
</TD>
</TR>
<TR>
<TD>
<P>Scolopendra</P>
</TD>
<TD>
<P>Centipede</P>
</TD>
<TD>
<P>strengthens cardiac contractility, decreases blood pressure, and increases blood vessel perfusion flow</P>
</TD>
<TD>
<P>6% to 15%</P>
</TD>
</TR>
<TR>
<TD>
<P>Periostracum cicadae</P>
</TD>
<TD>
<P>Cicada slough</P>
</TD>
<TD>
<P>anticonvulsion and slows heart rate down</P>
</TD>
<TD>
<P>10% to 20%</P>
</TD>
</TR>
<TR>
<TD>
<P>Radix paeoniae rubra</P>
</TD>
<TD>
<P>The root of common peony</P>
</TD>
<TD>
<P>anticoagulation and prevents thrombosis functions, and obviously inhibits to form platelet and fibrin thrombus, dilate coronary artery directly, has strong anti-myocardial ischemia function, and change the contents of lipoprotein, deduce calcium ion sediments on the arterious parietes, anti-atherosclerosis</P>
</TD>
<TD>
<P>5% to 15%</P>
</TD>
</TR>
<TR>
<TD>
<P>Borneolum syntheticum</P>
</TD>
<TD>
<P>Borneol</P>
</TD>
<TD>
<P>analgesia and sedation</P>
</TD>
<TD>
<P>2% to 10%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Tongxinluo capsule versus control</NAME>
<DICH_OUTCOME CHI2="3.847709082568476" CI_END="1.5884021521194325" CI_START="0.07184994849370609" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3378263056913613" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="18" I2="48.021018297336234" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.2009604668160211" LOG_CI_START="-1.1435735388576227" LOG_EFFECT_SIZE="-0.4713065360208008" METHOD="MH" NO="1" P_CHI2="0.14604308150607237" P_Q="0.6319706997864629" P_Z="0.16941906733189818" Q="0.2293978431248473" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.700335484286036" TOTALS="SUB" TOTAL_1="149" TOTAL_2="146" WEIGHT="200.0" Z="1.374072849598596">
<NAME>Events of AMI and PTCA or CABG</NAME>
<GROUP_LABEL_1>Tongxinluo</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tongxinluo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.4981961970140056" CI_END="2.590814378978802" CI_START="0.06958114152456886" DF="1" EFFECT_SIZE="0.4245842931240062" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" I2="71.41383891350688" ID="CMP-001.01.01" LOG_CI_END="0.41343629871604587" LOG_CI_START="-1.1575084506422588" LOG_EFFECT_SIZE="-0.3720360759631065" NO="1" P_CHI2="0.06143583645344386" P_Z="0.35323659932775553" STUDIES="2" TAU2="1.2185495037065597" TOTAL_1="119" TOTAL_2="119" WEIGHT="100.0" Z="0.928329669309056">
<NAME>Tongxinluo+routine vs routine</NAME>
<DICH_DATA CI_END="3.524147784514967" CI_START="0.2837565451692972" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5470541121842815" LOG_CI_START="-0.5470541121842816" LOG_EFFECT_SIZE="0.0" ORDER="3225" O_E="0.0" SE="0.6426845869171515" STUDY_ID="STD-Nong-2000" TOTAL_1="23" TOTAL_2="23" VAR="0.4130434782608696" WEIGHT="52.18974771553917"/>
<DICH_DATA CI_END="0.7248529438118955" CI_START="0.03832194932078017" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.13975009297250154" LOG_CI_START="-1.4165524077947858" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="3226" O_E="0.0" SE="0.7500000000000001" STUDY_ID="STD-Su-2000" TOTAL_1="96" TOTAL_2="96" VAR="0.5625000000000001" WEIGHT="47.81025228446084"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6032494228942107" CI_START="0.009056457232814973" DF="0" EFFECT_SIZE="0.18064516129032257" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.5566943257465988" LOG_CI_START="-2.0430416594027436" LOG_EFFECT_SIZE="-0.7431736668280723" NO="2" P_CHI2="1.0" P_Z="0.2624707805106987" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="27" WEIGHT="100.0" Z="1.1205704191211685">
<NAME>Tongxinluo+low weight molecular heparin(LWMH)+routine vs LWMH+routine</NAME>
<DICH_DATA CI_END="3.6032494228942107" CI_START="0.009056457232814973" EFFECT_SIZE="0.18064516129032257" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5566943257465988" LOG_CI_START="-2.0430416594027436" LOG_EFFECT_SIZE="-0.7431736668280723" ORDER="3227" O_E="0.0" SE="1.5270977865773971" STUDY_ID="STD-Lu-2002a" TOTAL_1="30" TOTAL_2="27" VAR="2.3320276497695853" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.780254682310321" CI_START="0.014281166317568032" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.8909938136107249" LOG_CI_START="-1.8452363230500497" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.49427533688550795" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="0.6835247247516405">
<NAME>Sudden death</NAME>
<GROUP_LABEL_1>Tongxinluo</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tongxinluo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.780254682310321" CI_START="0.014281166317568032" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.8909938136107249" LOG_CI_START="-1.8452363230500497" LOG_EFFECT_SIZE="-0.47712125471966244" NO="1" P_CHI2="1.0" P_Z="0.49427533688550795" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="0.6835247247516405">
<NAME>Tongxinluo+routine vs routine</NAME>
<DICH_DATA CI_END="7.780254682310321" CI_START="0.014281166317568032" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8909938136107249" LOG_CI_START="-1.8452363230500497" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="3228" O_E="0.0" SE="1.6072751268321592" STUDY_ID="STD-Nong-2000" TOTAL_1="23" TOTAL_2="23" VAR="2.5833333333333335" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.2475065013831501" CI_START="-2.3275065013831493" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0399999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.11337902760765008" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="23" TOTAL_2="23" UNITS="" WEIGHT="100.0" Z="1.5831862143856146">
<NAME>Angina scores</NAME>
<GROUP_LABEL_1>Tongxinluo</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tongxinluo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2475065013831501" CI_START="-2.3275065013831493" DF="0" EFFECT_SIZE="-1.0399999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" NO="1" P_CHI2="1.0" P_Z="0.11337902760765008" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="1.5831862143856146">
<NAME>Tongxinluo+routine vs routine</NAME>
<CONT_DATA CI_END="0.2475065013831501" CI_START="-2.3275065013831493" EFFECT_SIZE="-1.0399999999999996" ESTIMABLE="YES" MEAN_1="2.72" MEAN_2="3.76" ORDER="3229" SD_1="1.85" SD_2="2.55" SE="0.6569031428836635" STUDY_ID="STD-Nong-2000" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="205" TOTAL_2="206" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Frequency of angina attack</NAME>
<GROUP_LABEL_1>Tongxinluo</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tongxinluo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Tongxinluo+low weight molecular heparin+routine vs low weight molecular heparin+routine</NAME>
<CONT_DATA CI_END="-1.0210805856282845" CI_START="-1.3789194143717158" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="1.8" ORDER="3230" SD_1="0.3" SD_2="0.4" SE="0.09128709291752769" STUDY_ID="STD-Song-2002" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="112" TOTAL_2="111" WEIGHT="0.0" Z="0.0">
<NAME>Tongxinluo+routine vs routine</NAME>
<CONT_DATA CI_END="-5.078068940825258" CI_START="-5.741931059174743" EFFECT_SIZE="-5.41" ESTIMABLE="YES" MEAN_1="1.32" MEAN_2="6.73" ORDER="3231" SD_1="0.21" SD_2="0.92" SE="0.16935569316220703" STUDY_ID="STD-Cheng-2002" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0"/>
<CONT_DATA CI_END="-0.951791299913925" CI_START="-1.3682087000860754" EFFECT_SIZE="-1.1600000000000001" ESTIMABLE="YES" MEAN_1="3.96" MEAN_2="5.12" ORDER="3232" SD_1="0.62" SD_2="0.72" SE="0.10623088063270492" STUDY_ID="STD-Xiao-2004" TOTAL_1="80" TOTAL_2="80" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="63" TOTAL_2="65" WEIGHT="0.0" Z="0.0">
<NAME>Tongxinluo vs isosorbide mononitrate</NAME>
<CONT_DATA CI_END="0.5794810596220206" CI_START="0.02051894037798002" EFFECT_SIZE="0.30000000000000027" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="2.9" ORDER="3233" SD_1="0.5" SD_2="0.6" SE="0.14259499757471625" STUDY_ID="STD-Han-2004a" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0"/>
<CONT_DATA CI_END="-0.6727994115846787" CI_START="-1.1672005884153203" EFFECT_SIZE="-0.9199999999999995" ESTIMABLE="YES" MEAN_1="3.85" MEAN_2="4.77" ORDER="3234" SD_1="0.51" SD_2="0.53" SE="0.12612506676918933" STUDY_ID="STD-Zhang-2004" TOTAL_1="33" TOTAL_2="35" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.8591583206923867" CI_END="1.5453205955391118" CI_START="1.140361398656674" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.327487836366852" ESTIMABLE="YES" EVENTS_1="237" EVENTS_2="168" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.18901859277689503" LOG_CI_START="0.05704250797613271" LOG_EFFECT_SIZE="0.12303055037651389" METHOD="MH" NO="5" P_CHI2="0.9534769973649923" P_Q="0.9548534486300632" P_Z="2.5795551019180485E-4" Q="0.09239481795218535" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="521" TOTAL_2="489" WEIGHT="300.0" Z="3.6542294477084702">
<NAME>ECG marked improvement</NAME>
<GROUP_LABEL_1>Tongxinluo</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Not favours TXL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Not favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.5601321232019423" CI_END="1.5748111733382606" CI_START="1.0835475831984984" DF="6" EFFECT_SIZE="1.3062858955315502" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="113" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.19722848746308436" LOG_CI_START="0.034847987798693913" LOG_EFFECT_SIZE="0.11603823763088915" NO="1" P_CHI2="0.7359530092672353" P_Z="0.00509117133205095" STUDIES="7" TAU2="0.0" TOTAL_1="372" TOTAL_2="341" WEIGHT="100.00000000000001" Z="2.801207867399093">
<NAME>Tongxinluo+routine vs routine</NAME>
<DICH_DATA CI_END="1.5511610868182926" CI_START="0.663778917890218" EFFECT_SIZE="1.0147058823529411" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="20" LOG_CI_END="0.19065690128463483" LOG_CI_START="-0.1779765452225969" LOG_EFFECT_SIZE="0.006340178031018975" ORDER="3235" O_E="0.0" SE="0.21653711124333758" STUDY_ID="STD-Chang-2004" TOTAL_1="68" TOTAL_2="46" VAR="0.046888320545609555" WEIGHT="20.273720393219573"/>
<DICH_DATA CI_END="3.016156105160301" CI_START="0.8992231075124852" EFFECT_SIZE="1.646875" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="0.47945381526645636" LOG_CI_START="-0.046132541481175064" LOG_EFFECT_SIZE="0.21666063689264065" ORDER="3236" O_E="0.0" SE="0.3087320276479842" STUDY_ID="STD-Cheng-2002" TOTAL_1="32" TOTAL_2="31" VAR="0.09531546489563567" WEIGHT="8.6319481786257"/>
<DICH_DATA CI_END="2.2840070696148222" CI_START="0.6346085189848714" EFFECT_SIZE="1.203931203931204" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.3586974438338607" LOG_CI_START="-0.1974941022272734" LOG_EFFECT_SIZE="0.08060167080329365" ORDER="3237" O_E="0.0" SE="0.3267096673488661" STUDY_ID="STD-Jia-2001" TOTAL_1="37" TOTAL_2="35" VAR="0.10673920673920674" WEIGHT="9.606414203478367"/>
<DICH_DATA CI_END="2.1129476931877087" CI_START="0.9658622090411169" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="28" LOG_CI_END="0.3248887460626682" LOG_CI_START="-0.01508482609118185" LOG_EFFECT_SIZE="0.1549019599857432" ORDER="3238" O_E="0.0" SE="0.19970215917949508" STUDY_ID="STD-Su-2000" TOTAL_1="96" TOTAL_2="96" VAR="0.039880952380952385" WEIGHT="23.791807167337087"/>
<DICH_DATA CI_END="5.726208514582323" CI_START="0.6985424980270327" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.757867158405054" LOG_CI_START="-0.15580716707709164" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="3239" O_E="0.0" SE="0.5366968215490656" STUDY_ID="STD-Sun-2004" TOTAL_1="23" TOTAL_2="23" VAR="0.2880434782608696" WEIGHT="3.3988295953338694"/>
<DICH_DATA CI_END="1.6387273992330393" CI_START="0.8706130937530693" EFFECT_SIZE="1.1944444444444444" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="36" LOG_CI_END="0.21450671509871264" LOG_CI_START="-0.060174805474114135" LOG_EFFECT_SIZE="0.07716595481229925" ORDER="3240" O_E="0.0" SE="0.16134928487993416" STUDY_ID="STD-Xiao-2004" TOTAL_1="80" TOTAL_2="80" VAR="0.02603359173126615" WEIGHT="30.589466358004824"/>
<DICH_DATA CI_END="5.48559269683167" CI_START="0.6408833455736751" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.7392235582657227" LOG_CI_START="-0.19322101413824744" LOG_EFFECT_SIZE="0.27300127206373764" ORDER="3241" O_E="0.0" SE="0.5477225575051661" STUDY_ID="STD-Zhang-2000" TOTAL_1="36" TOTAL_2="30" VAR="0.3" WEIGHT="3.7078141040005845"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1400632656533461" CI_END="1.8089273439069729" CI_START="1.0412023729588635" DF="2" EFFECT_SIZE="1.3723918693238146" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="47" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.25742112364590525" LOG_CI_START="0.017535149219916002" LOG_EFFECT_SIZE="0.13747813643291062" NO="2" P_CHI2="0.9323643393627171" P_Z="0.02467185269173478" STUDIES="3" TAU2="0.0" TOTAL_1="119" TOTAL_2="118" WEIGHT="100.00000000000001" Z="2.2465022952254454">
<NAME>Tongxinluo vs Isosorbide mononitrate</NAME>
<DICH_DATA CI_END="2.4004855766555826" CI_START="0.7907865072794945" EFFECT_SIZE="1.3777777777777778" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.3802991008497754" LOG_CI_START="-0.10194074940395506" LOG_EFFECT_SIZE="0.1391791757229102" ORDER="3242" O_E="0.0" SE="0.28327007516479913" STUDY_ID="STD-Jia-1999" TOTAL_1="30" TOTAL_2="31" VAR="0.08024193548387096" WEIGHT="25.058527144273445"/>
<DICH_DATA CI_END="2.183007283679146" CI_START="0.9489401995286288" EFFECT_SIZE="1.4392857142857143" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="20" LOG_CI_END="0.3390551847500846" LOG_CI_START="-0.022761155152304147" LOG_EFFECT_SIZE="0.15814701479889023" ORDER="3243" O_E="0.0" SE="0.2125327090784309" STUDY_ID="STD-Yang-2001a" TOTAL_1="56" TOTAL_2="52" VAR="0.04517015242821694" WEIGHT="44.03288514652164"/>
<DICH_DATA CI_END="2.0843666225448083" CI_START="0.7771352185471774" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.31897411009025683" LOG_CI_START="-0.1095034090502309" LOG_EFFECT_SIZE="0.10473535052001298" ORDER="3244" O_E="0.0" SE="0.2516898157410493" STUDY_ID="STD-Zhang-2004" TOTAL_1="33" TOTAL_2="35" VAR="0.06334776334776335" WEIGHT="30.908587709204927"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9318252927248762" CI_START="0.6448627770186227" DF="0" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="0.46713808716071203" LOG_CI_START="-0.1905326908281491" LOG_EFFECT_SIZE="0.13830269816628146" NO="3" P_CHI2="1.0" P_Z="0.40975306748698115" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.8243282701400988">
<NAME>Tongxinluo+low weight molecular heparin(LWMH)+routine vs LWMH+routine</NAME>
<DICH_DATA CI_END="2.9318252927248762" CI_START="0.6448627770186227" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.46713808716071203" LOG_CI_START="-0.1905326908281491" LOG_EFFECT_SIZE="0.13830269816628146" ORDER="3245" O_E="0.0" SE="0.3863190705135125" STUDY_ID="STD-Song-2002" TOTAL_1="30" TOTAL_2="30" VAR="0.14924242424242426" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.980489671917214" CI_END="0.8329897240514277" CI_START="0.5979977412582091" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.70578040031872" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="184" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.07936035611456672" LOG_CI_START="-0.22330045641451296" LOG_EFFECT_SIZE="-0.15133040626453984" METHOD="MH" NO="6" P_CHI2="0.43907725645676476" P_Q="0.4803318773455415" P_Z="3.769227902421945E-5" Q="1.4665563700666417" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="485" TOTAL_2="459" WEIGHT="300.0" Z="4.12118854198719">
<NAME>No improvement and worse on ECG</NAME>
<GROUP_LABEL_1>Tongxinluo</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tongxinluo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.217793145282422" CI_END="0.8199737726228933" CI_START="0.5570493967164735" DF="5" EFFECT_SIZE="0.6758445792953536" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="136" I2="30.726748476187353" ID="CMP-001.06.01" LOG_CI_END="-0.08620003857642348" LOG_CI_START="-0.2541062917738591" LOG_EFFECT_SIZE="-0.1701531651751413" NO="1" P_CHI2="0.2049402332303647" P_Z="7.115682326798434E-5" STUDIES="6" TAU2="0.0" TOTAL_1="336" TOTAL_2="311" WEIGHT="99.99999999999999" Z="3.972384223315694">
<NAME>Tongxinluo+routine vs routine</NAME>
<DICH_DATA CI_END="1.0394862419761879" CI_START="0.15848260205529452" EFFECT_SIZE="0.40588235294117647" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.016818745641163483" LOG_CI_START="-0.8000184069232006" LOG_EFFECT_SIZE="-0.3915998306410186" ORDER="3246" O_E="0.0" SE="0.479814186825424" STUDY_ID="STD-Chang-2004" TOTAL_1="68" TOTAL_2="46" VAR="0.2302216538789429" WEIGHT="8.622407390634905"/>
<DICH_DATA CI_END="1.1320281065759554" CI_START="0.24036741701624742" EFFECT_SIZE="0.5216346153846154" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.053857209872841295" LOG_CI_START="-0.6191244034292677" LOG_EFFECT_SIZE="-0.2826335967782132" ORDER="3247" O_E="0.0" SE="0.39531273096637143" STUDY_ID="STD-Cheng-2002" TOTAL_1="32" TOTAL_2="31" VAR="0.15627215526409075" WEIGHT="9.545029133834493"/>
<DICH_DATA CI_END="2.2447579168405243" CI_START="0.39862371168781197" EFFECT_SIZE="0.9459459459459459" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.351169511909847" LOG_CI_START="-0.3994368713432857" LOG_EFFECT_SIZE="-0.024133679716719363" ORDER="3248" O_E="0.0" SE="0.4409099050844111" STUDY_ID="STD-Jia-2001" TOTAL_1="37" TOTAL_2="35" VAR="0.1944015444015444" WEIGHT="5.94269842707484"/>
<DICH_DATA CI_END="1.0182804190582722" CI_START="0.6660254673940771" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="68" LOG_CI_END="0.007867392616937335" LOG_CI_START="-0.1765091640170092" LOG_EFFECT_SIZE="-0.08432088570003593" ORDER="3249" O_E="0.0" SE="0.10830370204545502" STUDY_ID="STD-Su-2000" TOTAL_1="96" TOTAL_2="96" VAR="0.011729691876750699" WEIGHT="49.14772212661896"/>
<DICH_DATA CI_END="1.1032492318560192" CI_START="0.22660337553955942" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.04267363373916371" LOG_CI_START="-0.6447336250671262" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="3250" O_E="0.0" SE="0.4037864265436241" STUDY_ID="STD-Sun-2004" TOTAL_1="23" TOTAL_2="23" VAR="0.16304347826086957" WEIGHT="8.673127434109228"/>
<DICH_DATA CI_END="0.8874875345860553" CI_START="0.2596092801545251" EFFECT_SIZE="0.48" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="25" LOG_CI_END="-0.05183773821485145" LOG_CI_START="-0.585679787033974" LOG_EFFECT_SIZE="-0.3187587626244128" ORDER="3251" O_E="0.0" SE="0.31358146203711296" STUDY_ID="STD-Xiao-2004" TOTAL_1="80" TOTAL_2="80" VAR="0.09833333333333333" WEIGHT="18.069015487727558"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0233566000627976" CI_END="1.242872145533043" CI_START="0.4304620352036825" DF="2" EFFECT_SIZE="0.7314432809617716" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="26" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.09442645499289345" LOG_CI_START="-0.3660651453220684" LOG_EFFECT_SIZE="-0.13581934516458746" NO="2" P_CHI2="0.5994886863420124" P_Z="0.24761566540045243" STUDIES="3" TAU2="0.0" TOTAL_1="119" TOTAL_2="118" WEIGHT="100.0" Z="1.156160176404228">
<NAME>Tongxinluo capsule vs Isosorbide mononitrate</NAME>
<DICH_DATA CI_END="2.183069534263124" CI_START="0.37448067882412045" EFFECT_SIZE="0.9041666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.33906756890466827" LOG_CI_START="-0.42657058463082126" LOG_EFFECT_SIZE="-0.04375150786307651" ORDER="3252" O_E="0.0" SE="0.4497396413567304" STUDY_ID="STD-Jia-1999" TOTAL_1="30" TOTAL_2="31" VAR="0.2022657450076805" WEIGHT="30.1831166616092"/>
<DICH_DATA CI_END="1.2713502511549504" CI_START="0.20178205957566725" EFFECT_SIZE="0.5064935064935064" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.10426521317308943" LOG_CI_START="-0.6951174494650547" LOG_EFFECT_SIZE="-0.2954261181459827" ORDER="3253" O_E="0.0" SE="0.46956133304164377" STUDY_ID="STD-Yang-2001a" TOTAL_1="56" TOTAL_2="52" VAR="0.2204878454878455" WEIGHT="43.75620338258593"/>
<DICH_DATA CI_END="2.4252720192671795" CI_START="0.3407643655747344" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3847604562749209" LOG_CI_START="-0.46754582659137106" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="3254" O_E="0.0" SE="0.500648929539803" STUDY_ID="STD-Zhang-2004" TOTAL_1="33" TOTAL_2="35" VAR="0.2506493506493507" WEIGHT="26.060679955804858"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2223932534460673" CI_START="0.6101700631055956" DF="0" EFFECT_SIZE="0.8636363636363636" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="0.08721094430816058" LOG_CI_START="-0.21454910404691518" LOG_EFFECT_SIZE="-0.06366907986937727" NO="3" P_CHI2="1.0" P_Z="0.4081945329408221" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.00000000000001" Z="0.8270750495502738">
<NAME>Tongxinluo+low weight molecular heparin(LWMH)+routine vs LWMH+routine</NAME>
<DICH_DATA CI_END="1.2223932534460673" CI_START="0.6101700631055956" EFFECT_SIZE="0.8636363636363636" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.08721094430816058" LOG_CI_START="-0.21454910404691518" LOG_EFFECT_SIZE="-0.06366907986937727" ORDER="3255" O_E="0.0" SE="0.17725534614010152" STUDY_ID="STD-Song-2002" TOTAL_1="30" TOTAL_2="30" VAR="0.0314194577352472" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.618223908404529" CI_END="1.8152837188812119" CI_START="1.1519647358318708" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4460784313725488" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="34" I2="78.34665404204118" I2_Q="63.86359871050751" ID="CMP-001.07" LOG_CI_END="0.25894451252084066" LOG_CI_START="0.061439184583687655" LOG_EFFECT_SIZE="0.16019184855226418" METHOD="MH" NO="7" P_CHI2="0.031634042235584636" P_Q="0.09620884219330306" P_Z="0.0014760073289205868" Q="2.767292714038942" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="72" TOTAL_2="60" WEIGHT="200.0" Z="3.1793598386291557">
<NAME>Nitroglycerin consumption</NAME>
<GROUP_LABEL_1>Tongxinluo</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tongxinluo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.488354888732443" CI_START="1.1466723219361068" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="10" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.5426206615752909" LOG_CI_START="0.059439329752671466" LOG_EFFECT_SIZE="0.3010299956639812" NO="1" P_CHI2="1.0" P_Z="0.014598856065978749" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="30" WEIGHT="100.0" Z="2.442180237146453">
<NAME>Withdraw</NAME>
<DICH_DATA CI_END="3.4883548887324425" CI_START="1.146672321936107" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="10" LOG_CI_END="0.5426206615752909" LOG_CI_START="0.05943932975267155" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="3256" O_E="0.0" SE="0.2838231060987733" STUDY_ID="STD-Zhang-2000" TOTAL_1="36" TOTAL_2="30" VAR="0.08055555555555555" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.465532012455542" CI_START="1.0077569542038896" DF="0" EFFECT_SIZE="1.2152777777777777" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="24" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.16599530942129784" LOG_CI_START="0.0033558037607917045" LOG_EFFECT_SIZE="0.08467555659104475" NO="2" P_CHI2="1.0" P_Z="0.04126619901563988" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="30" WEIGHT="100.0" Z="2.040845372904147">
<NAME>Reducing to half dose (including withdraw)</NAME>
<DICH_DATA CI_END="1.465532012455542" CI_START="1.0077569542038896" EFFECT_SIZE="1.2152777777777777" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="24" LOG_CI_END="0.16599530942129784" LOG_CI_START="0.0033558037607917045" LOG_EFFECT_SIZE="0.08467555659104475" ORDER="3257" O_E="0.0" SE="0.09553525070351848" STUDY_ID="STD-Zhang-2000" TOTAL_1="36" TOTAL_2="30" VAR="0.00912698412698413" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.08" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="55" TOTAL_2="54" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Nitroglycerin consumption</NAME>
<GROUP_LABEL_1>Tongxinluo</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tongxinluo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>Tongxinluo+routine vs routine</NAME>
<CONT_DATA CI_END="-2.2364307532812107" CI_START="-3.6920746199780576" EFFECT_SIZE="-2.964252686629634" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="1.12" ORDER="3258" SD_1="0.1" SD_2="0.43" SE="0.3713445446392842" STUDY_ID="STD-Cheng-2002" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0"/>
<CONT_DATA CI_END="-0.36791484717066525" CI_START="-1.5977994385436205" EFFECT_SIZE="-0.9828571428571429" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="4.0" ORDER="3259" SD_1="1.0" SD_2="1.0" SE="0.31375183449138044" STUDY_ID="STD-Nong-2000" TOTAL_1="23" TOTAL_2="23" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="12.132323439278691" CI_END="1.3290507687605504" CI_START="1.0509018269008283" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1818214251461228" ESTIMABLE="YES" EVENTS_1="332" EVENTS_2="251" I2="0.0" I2_Q="1.8907668394137809" ID="CMP-001.09" LOG_CI_END="0.1235415709889583" LOG_CI_START="0.02156214702094899" LOG_EFFECT_SIZE="0.07255185900495362" METHOD="MH" NO="9" P_CHI2="0.5168244074937678" P_Q="0.3608576604473187" P_Z="0.005290717810608625" Q="2.038544116155081" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="626" TOTAL_2="561" WEIGHT="300.0" Z="2.7887788561297335">
<NAME>Symptom marked improvement</NAME>
<GROUP_LABEL_1>Tongxinluo</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Not favours TXL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Not favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.429866437634606" CI_END="1.3968724495692535" CI_START="1.0553692238446428" DF="9" EFFECT_SIZE="1.2141730489974927" ESTIMABLE="YES" EVENTS_1="249" EVENTS_2="177" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.14515675187135157" LOG_CI_START="0.023404425344867433" LOG_EFFECT_SIZE="0.08428058860810947" NO="1" P_CHI2="0.49147228683557864" P_Z="0.006657838616266177" STUDIES="10" TAU2="0.0" TOTAL_1="477" TOTAL_2="416" WEIGHT="99.99999999999997" Z="2.713490952992986">
<NAME>Tongxinluo+routine vs routine</NAME>
<DICH_DATA CI_END="1.3308943201154904" CI_START="0.5372473628152332" EFFECT_SIZE="0.8455882352941176" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="20" LOG_CI_END="0.1241435716182966" LOG_CI_START="-0.2698257076515083" LOG_EFFECT_SIZE="-0.07284106801660584" ORDER="3260" O_E="0.0" SE="0.23141950482246781" STUDY_ID="STD-Chang-2004" TOTAL_1="68" TOTAL_2="46" VAR="0.05355498721227621" WEIGHT="12.789494832052387"/>
<DICH_DATA CI_END="2.218041277382448" CI_START="0.8634908242449656" EFFECT_SIZE="1.3839285714285714" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" LOG_CI_END="0.34596962403704506" LOG_CI_START="-0.06374227303682532" LOG_EFFECT_SIZE="0.14111367550010986" ORDER="3261" O_E="0.0" SE="0.24066679644779085" STUDY_ID="STD-Cheng-2002" TOTAL_1="32" TOTAL_2="31" VAR="0.057920506912442396" WEIGHT="7.623542017537109"/>
<DICH_DATA CI_END="1.8121247726161513" CI_START="0.6963246663543761" EFFECT_SIZE="1.1233108108108107" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.2581880974208734" LOG_CI_START="-0.15718822026050377" LOG_EFFECT_SIZE="0.0504999385801848" ORDER="3262" O_E="0.0" SE="0.24399410515197456" STUDY_ID="STD-Jia-2001" TOTAL_1="37" TOTAL_2="35" VAR="0.05953312334891282" WEIGHT="8.814720457777282"/>
<DICH_DATA CI_END="2.5649013696875738" CI_START="1.145765503864988" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="14" LOG_CI_END="0.4090706694774639" LOG_CI_START="0.059095742589272" LOG_EFFECT_SIZE="0.23408320603336796" ORDER="3263" O_E="0.0" SE="0.20557700445795185" STUDY_ID="STD-Liu-2003" TOTAL_1="60" TOTAL_2="30" VAR="0.04226190476190476" WEIGHT="10.005898898017456"/>
<DICH_DATA CI_END="1.518679818910661" CI_START="0.8502926673351359" EFFECT_SIZE="1.1363636363636365" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="44" LOG_CI_END="0.181466221830239" LOG_CI_START="-0.07043156613057616" LOG_EFFECT_SIZE="0.05551732784983141" ORDER="3264" O_E="0.0" SE="0.14796600756234318" STUDY_ID="STD-Su-2000" TOTAL_1="96" TOTAL_2="96" VAR="0.021893939393939396" WEIGHT="23.585333116755432"/>
<DICH_DATA CI_END="4.1631174001888755" CI_START="0.6149238068289538" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.619418658192876" LOG_CI_START="-0.21117869288102636" LOG_EFFECT_SIZE="0.2041199826559248" ORDER="3265" O_E="0.0" SE="0.4878969955440078" STUDY_ID="STD-Sun-2004" TOTAL_1="23" TOTAL_2="23" VAR="0.23804347826086955" WEIGHT="2.68015149054039"/>
<DICH_DATA CI_END="2.9351216004316285" CI_START="0.8721955504751613" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.4676260985316693" LOG_CI_START="-0.05938613321981964" LOG_EFFECT_SIZE="0.2041199826559248" ORDER="3266" O_E="0.0" SE="0.3095695936834452" STUDY_ID="STD-Xiao-2002" TOTAL_1="30" TOTAL_2="30" VAR="0.09583333333333335" WEIGHT="5.36030298108078"/>
<DICH_DATA CI_END="1.4114069030451861" CI_START="0.8108238504399927" EFFECT_SIZE="1.069767441860465" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="43" LOG_CI_END="0.14965223719270296" LOG_CI_START="-0.09107348498872798" LOG_EFFECT_SIZE="0.029289376101987508" ORDER="3267" O_E="0.0" SE="0.14140348082091536" STUDY_ID="STD-Xiao-2004" TOTAL_1="80" TOTAL_2="80" VAR="0.019994944388270982" WEIGHT="23.049302818647355"/>
<DICH_DATA CI_END="2.3452615705961373" CI_START="0.5569197335406775" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.37019128727770284" LOG_CI_START="-0.25420739332232944" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="3268" O_E="0.0" SE="0.36677487580777607" STUDY_ID="STD-Yao-2003" TOTAL_1="15" TOTAL_2="15" VAR="0.13452380952380955" WEIGHT="3.752212086756546"/>
<DICH_DATA CI_END="5.48559269683167" CI_START="0.6408833455736751" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.7392235582657227" LOG_CI_START="-0.19322101413824744" LOG_EFFECT_SIZE="0.27300127206373764" ORDER="3269" O_E="0.0" SE="0.5477225575051661" STUDY_ID="STD-Zhang-2000" TOTAL_1="36" TOTAL_2="30" VAR="0.3" WEIGHT="2.3390413008352495"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5260347925630766" CI_END="1.299878260264019" CI_START="0.832301157096861" DF="2" EFFECT_SIZE="1.0401395003088758" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="66" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.11390268048276594" LOG_CI_START="-0.07971950159385387" LOG_EFFECT_SIZE="0.017091589444456056" NO="2" P_CHI2="0.466257540774453" P_Z="0.7293251540206984" STUDIES="3" TAU2="0.0" TOTAL_1="119" TOTAL_2="118" WEIGHT="100.00000000000003" Z="0.34602336767822095">
<NAME>Tongxinluo vs isosorbide mononitrate</NAME>
<DICH_DATA CI_END="1.4067842646468722" CI_START="0.6076367289142828" EFFECT_SIZE="0.9245614035087719" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" LOG_CI_END="0.14822750194284848" LOG_CI_START="-0.21635598286273808" LOG_EFFECT_SIZE="-0.03406424045994479" ORDER="3270" O_E="0.0" SE="0.21415814369215744" STUDY_ID="STD-Jia-1999" TOTAL_1="30" TOTAL_2="31" VAR="0.04586371050967075" WEIGHT="28.32994318960099"/>
<DICH_DATA CI_END="1.7519465783050652" CI_START="0.8575464165451706" EFFECT_SIZE="1.2257142857142858" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="25" LOG_CI_END="0.24352085919447747" LOG_CI_START="-0.06674236352558019" LOG_EFFECT_SIZE="0.08838924783444863" ORDER="3271" O_E="0.0" SE="0.18225015285348384" STUDY_ID="STD-Yang-2001a" TOTAL_1="56" TOTAL_2="52" VAR="0.033215118215118224" WEIGHT="39.3011232682249"/>
<DICH_DATA CI_END="1.3503284142878016" CI_START="0.6213419024234705" EFFECT_SIZE="0.9159779614325069" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.13043940639661764" LOG_CI_START="-0.20666935719059593" LOG_EFFECT_SIZE="-0.038114975396989124" ORDER="3272" O_E="0.0" SE="0.19801935644642168" STUDY_ID="STD-Zhang-2004" TOTAL_1="33" TOTAL_2="35" VAR="0.039211665527455" WEIGHT="32.36893354217413"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1586165550278653" CI_START="0.7853517376306273" DF="0" EFFECT_SIZE="1.575" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="0.49949690727803203" LOG_CI_START="-0.10493579102679343" LOG_EFFECT_SIZE="0.19728055812561932" NO="3" P_CHI2="1.0" P_Z="0.2007478842592918" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="27" WEIGHT="100.0" Z="1.2794237964312583">
<NAME>Tongxinluo+low weight molecular heparin(LWMH)+routine vs LWMH+routine</NAME>
<DICH_DATA CI_END="3.1586165550278653" CI_START="0.7853517376306273" EFFECT_SIZE="1.575" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.49949690727803203" LOG_CI_START="-0.10493579102679343" LOG_EFFECT_SIZE="0.19728055812561932" ORDER="3273" O_E="0.0" SE="0.35504675897436533" STUDY_ID="STD-Lu-2002a" TOTAL_1="30" TOTAL_2="27" VAR="0.12605820105820106" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.116244172191706" CI_END="0.6057202461537011" CI_START="0.34525692830458166" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.45730636514149015" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="122" I2="0.9594076393615535" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-0.21772790983367482" LOG_CI_START="-0.46185759763200057" LOG_EFFECT_SIZE="-0.33979275373283774" METHOD="MH" NO="10" P_CHI2="0.43638980145891815" P_Q="0.5418048598297511" P_Z="4.870748960249231E-8" Q="1.2256998178032152" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="590" TOTAL_2="531" WEIGHT="300.0" Z="5.4559653562021015">
<NAME>No improvement and worse of symptom</NAME>
<GROUP_LABEL_1>Tongxinluo</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tongxinluo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.135071333253691" CI_END="0.6232137398963581" CI_START="0.33124689925583617" DF="8" EFFECT_SIZE="0.4543540677866787" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="95" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="-0.20536298040707215" LOG_CI_START="-0.4798481783906314" LOG_EFFECT_SIZE="-0.3426055793988518" NO="1" P_CHI2="0.5221322425050675" P_Z="9.943347904261403E-7" STUDIES="9" TAU2="0.0" TOTAL_1="441" TOTAL_2="386" WEIGHT="100.00000000000001" Z="4.892756341377998">
<NAME>Tongxinluo+routine vs routine</NAME>
<DICH_DATA CI_END="0.9091439363110221" CI_START="0.23790884932605508" EFFECT_SIZE="0.4650735294117647" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="-0.04136735352501989" LOG_CI_START="-0.623589403519704" LOG_EFFECT_SIZE="-0.33247837852236195" ORDER="3274" O_E="0.0" SE="0.342000114212506" STUDY_ID="STD-Chang-2004" TOTAL_1="68" TOTAL_2="46" VAR="0.11696407812136712" WEIGHT="19.125587001833203"/>
<DICH_DATA CI_END="0.8141594574996772" CI_START="0.04610775217828246" EFFECT_SIZE="0.19375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.08929052787477304" LOG_CI_START="-1.336226049768531" LOG_EFFECT_SIZE="-0.712758288821652" ORDER="3275" O_E="0.0" SE="0.7324560979907745" STUDY_ID="STD-Cheng-2002" TOTAL_1="32" TOTAL_2="31" VAR="0.536491935483871" WEIGHT="10.17888383851067"/>
<DICH_DATA CI_END="1.8386523069286138" CI_START="0.2737509004393022" EFFECT_SIZE="0.7094594594594594" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2644996109897241" LOG_CI_START="-0.5626444436397627" LOG_EFFECT_SIZE="-0.14907241632501933" ORDER="3276" O_E="0.0" SE="0.48586851211846505" STUDY_ID="STD-Jia-2001" TOTAL_1="37" TOTAL_2="35" VAR="0.23606821106821102" WEIGHT="8.238534106794573"/>
<DICH_DATA CI_END="1.0699280794856165" CI_START="0.01460378533808736" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.02935458541202665" LOG_CI_START="-1.8355345593959134" LOG_EFFECT_SIZE="-0.9030899869919435" ORDER="3277" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Liu-2003" TOTAL_1="60" TOTAL_2="30" VAR="1.2" WEIGHT="5.343914015218101"/>
<DICH_DATA CI_END="0.7045903712032815" CI_START="0.15769603964550122" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="24" LOG_CI_END="-0.15206329609922062" LOG_CI_START="-0.8021792133401043" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="3278" O_E="0.0" SE="0.3818813079129867" STUDY_ID="STD-Su-2000" TOTAL_1="96" TOTAL_2="96" VAR="0.14583333333333334" WEIGHT="24.047613068481457"/>
<DICH_DATA CI_END="1.2381104542323778" CI_START="0.11358033487180817" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.09275939066457378" LOG_CI_START="-0.9446968552091362" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="3279" O_E="0.0" SE="0.6094069343174583" STUDY_ID="STD-Sun-2004" TOTAL_1="23" TOTAL_2="23" VAR="0.3713768115942029" WEIGHT="8.015871022827152"/>
<DICH_DATA CI_END="1.4415182764824825" CI_START="0.24973668795823606" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.15882015301987212" LOG_CI_START="-0.6025176522525849" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="3280" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Xiao-2002" TOTAL_1="30" TOTAL_2="30" VAR="0.2" WEIGHT="10.019838778533941"/>
<DICH_DATA CI_END="1.8176965897306465" CI_START="0.38204640332595335" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.2595213924158669" LOG_CI_START="-0.4178838845111165" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="3281" O_E="0.0" SE="0.39791121287711073" STUDY_ID="STD-Xiao-2004" TOTAL_1="80" TOTAL_2="80" VAR="0.15833333333333333" WEIGHT="12.023806534240729"/>
<DICH_DATA CI_END="2.8531415452949767" CI_START="0.03894342756823292" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45532331768430767" LOG_CI_START="-1.4095658271236327" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="3282" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Yao-2003" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="3.005951633560182"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.426855105479421" CI_END="1.228127752371727" CI_START="0.2829120922548991" DF="2" EFFECT_SIZE="0.5894507544992982" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" I2="41.63745071094281" ID="CMP-001.10.02" LOG_CI_END="0.08924354535914518" LOG_CI_START="-0.54834848949125" LOG_EFFECT_SIZE="-0.22955247206605245" NO="2" P_CHI2="0.1802472038644245" P_Z="0.15815824691522787" STUDIES="3" TAU2="0.0" TOTAL_1="119" TOTAL_2="118" WEIGHT="100.0" Z="1.4112929686054427">
<NAME>Tongxinluo vs isosorbide mononitrate</NAME>
<DICH_DATA CI_END="3.7606650944560744" CI_START="0.2839332274899679" EFFECT_SIZE="1.0333333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5752646591054879" LOG_CI_START="-0.5467837808762671" LOG_EFFECT_SIZE="0.014240439114610285" ORDER="3283" O_E="0.0" SE="0.6590968078746382" STUDY_ID="STD-Jia-1999" TOTAL_1="30" TOTAL_2="31" VAR="0.43440860215053767" WEIGHT="22.941110319751097"/>
<DICH_DATA CI_END="0.9109821197264014" CI_START="0.046740758176170946" EFFECT_SIZE="0.20634920634920634" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.04049014704496544" LOG_CI_START="-1.3303042472485245" LOG_EFFECT_SIZE="-0.685397197146745" ORDER="3284" O_E="0.0" SE="0.7576431871423375" STUDY_ID="STD-Yang-2001a" TOTAL_1="56" TOTAL_2="52" VAR="0.574023199023199" WEIGHT="54.42141170296511"/>
<DICH_DATA CI_END="3.8985134586574195" CI_START="0.28854208859950886" EFFECT_SIZE="1.0606060606060606" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5908990378540036" LOG_CI_START="-0.5397908289092271" LOG_EFFECT_SIZE="0.025554104472388137" ORDER="3285" O_E="0.0" SE="0.6641728247418296" STUDY_ID="STD-Zhang-2004" TOTAL_1="33" TOTAL_2="35" VAR="0.44112554112554114" WEIGHT="22.637477977283805"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8793912001882924" CI_START="0.08289825959640135" DF="0" EFFECT_SIZE="0.27" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="-0.055817884553005404" LOG_CI_START="-1.08145458712902" LOG_EFFECT_SIZE="-0.5686362358410126" NO="3" P_CHI2="1.0" P_Z="0.02975797728272644" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="27" WEIGHT="100.0" Z="2.173296918399248">
<NAME>Tongxinluo+low weight molecular heparin(LWMH)+routine vs LWMH+routine</NAME>
<DICH_DATA CI_END="0.8793912001882924" CI_START="0.08289825959640135" EFFECT_SIZE="0.27" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="-0.055817884553005404" LOG_CI_START="-1.08145458712902" LOG_EFFECT_SIZE="-0.5686362358410126" ORDER="3286" O_E="0.0" SE="0.6024640760767093" STUDY_ID="STD-Lu-2002a" TOTAL_1="30" TOTAL_2="27" VAR="0.362962962962963" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="79.3911725309605" CI_END="-8.80819238516527" CI_START="-11.517768577244055" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="MD" EFFECT_SIZE="-10.162980481204663" ESTIMABLE="YES" I2="88.66372707055028" I2_Q="96.18470417503292" ID="CMP-001.11" NO="11" P_CHI2="2.1360690993788012E-13" P_Q="3.3306690738754696E-16" P_Z="6.191778485591019E-49" Q="78.63086213048473" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="342" TOTAL_2="315" UNITS="" WEIGHT="400.0" Z="14.70272419500615">
<NAME>ET level</NAME>
<GROUP_LABEL_1>TXL or after</GROUP_LABEL_1>
<GROUP_LABEL_2>Control or before</GROUP_LABEL_2>
<GRAPH_LABEL_1>TXL or after</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control or before</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.09668173874543963" CI_END="-13.029861321547383" CI_START="-17.93568386060018" DF="2" EFFECT_SIZE="-15.48277259107378" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.01" NO="1" P_CHI2="0.9528089504413528" P_Z="3.737697883480668E-35" STUDIES="3" TAU2="0.0" TOTAL_1="93" TOTAL_2="93" WEIGHT="99.99999999999999" Z="12.371289999897787">
<NAME>Change from baseline: tongxinluo capsule</NAME>
<CONT_DATA CI_END="-11.920009613204805" CI_START="-20.079990386795195" EFFECT_SIZE="-16.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="61.0" ORDER="3287" SD_1="7.0" SD_2="9.0" SE="2.081665999466133" STUDY_ID="STD-Han-2004a" TOTAL_1="30" TOTAL_2="30" WEIGHT="36.144764330096606"/>
<CONT_DATA CI_END="-10.719832435513759" CI_START="-19.660167564486237" EFFECT_SIZE="-15.189999999999998" ESTIMABLE="YES" MEAN_1="48.24" MEAN_2="63.43" ORDER="3288" SD_1="7.54" SD_2="9.96" SE="2.280739646108984" STUDY_ID="STD-Jia-1999" TOTAL_1="30" TOTAL_2="30" WEIGHT="30.110368534016345"/>
<CONT_DATA CI_END="-10.967419116207088" CI_START="-19.412580883792906" EFFECT_SIZE="-15.189999999999998" ESTIMABLE="YES" MEAN_1="48.34" MEAN_2="63.53" ORDER="3289" SD_1="7.48" SD_2="9.86" SE="2.154417589863941" STUDY_ID="STD-Zhang-2004" TOTAL_1="33" TOTAL_2="33" WEIGHT="33.744867135887034"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.49607034230774166" CI_END="-11.655663723211191" CI_START="-16.37169327359205" DF="2" EFFECT_SIZE="-14.013678498401621" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.02" NO="2" P_CHI2="0.7803325068282778" P_Z="2.3473312555228217E-31" STUDIES="3" TAU2="0.0" TOTAL_1="96" TOTAL_2="96" WEIGHT="100.0" Z="11.648063208413264">
<NAME>Change from baseline: isosorbide mononitrate</NAME>
<CONT_DATA CI_END="-11.19612107299914" CI_START="-18.80387892700086" EFFECT_SIZE="-15.0" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="62.0" ORDER="3290" SD_1="7.0" SD_2="8.0" SE="1.9407902170679516" STUDY_ID="STD-Han-2004a" TOTAL_1="30" TOTAL_2="30" WEIGHT="38.42728251258288"/>
<CONT_DATA CI_END="-8.579680093965283" CI_START="-17.320319906034708" EFFECT_SIZE="-12.949999999999996" ESTIMABLE="YES" MEAN_1="49.63" MEAN_2="62.58" ORDER="3291" SD_1="7.86" SD_2="9.61" SE="2.229796027124599" STUDY_ID="STD-Jia-1999" TOTAL_1="31" TOTAL_2="31" WEIGHT="29.11163432345581"/>
<CONT_DATA CI_END="-9.661289790439668" CI_START="-17.938710209560327" EFFECT_SIZE="-13.799999999999997" ESTIMABLE="YES" MEAN_1="49.78" MEAN_2="63.58" ORDER="3292" SD_1="7.86" SD_2="9.71" SE="2.111625643229135" STUDY_ID="STD-Zhang-2004" TOTAL_1="35" TOTAL_2="35" WEIGHT="32.46108316396131"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.1675583194226205" CI_END="0.9430004140454387" CI_START="-3.9334104668538146" DF="2" EFFECT_SIZE="-1.4952050264041878" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.03" NO="3" P_CHI2="0.919634358059418" P_Z="0.22939134956127927" STUDIES="3" TAU2="0.0" TOTAL_1="93" TOTAL_2="96" WEIGHT="99.99999999999997" Z="1.2019282512613254">
<NAME>Tongxinluo vs Isosorbide mononitrate</NAME>
<CONT_DATA CI_END="2.985987257168869" CI_START="-4.985987257168869" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-16.0" MEAN_2="-15.0" ORDER="3293" SD_1="8.19" SD_2="7.55" SE="2.033704337737748" STUDY_ID="STD-Han-2004a" TOTAL_1="30" TOTAL_2="30" WEIGHT="37.41698415690941"/>
<CONT_DATA CI_END="2.245691138828744" CI_START="-6.725691138828744" EFFECT_SIZE="-2.24" ESTIMABLE="YES" MEAN_1="-15.19" MEAN_2="-12.95" ORDER="3294" SD_1="9.0" SD_2="8.87" SE="2.288659982638101" STUDY_ID="STD-Jia-1999" TOTAL_1="30" TOTAL_2="31" WEIGHT="29.544854660721747"/>
<CONT_DATA CI_END="2.8519189103969262" CI_START="-5.631918910396924" EFFECT_SIZE="-1.3899999999999988" ESTIMABLE="YES" MEAN_1="-15.19" MEAN_2="-13.8" ORDER="3295" SD_1="8.91" SD_2="8.93" SE="2.1642841112676763" STUDY_ID="STD-Zhang-2004" TOTAL_1="33" TOTAL_2="35" WEIGHT="33.03816118236883"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.5598050132021744" CI_START="-12.000194986797824" DF="0" EFFECT_SIZE="-6.279999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.04" NO="4" P_CHI2="1.0" P_Z="0.03141506248295026" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="30" WEIGHT="100.0" Z="2.1517752194321442">
<NAME>Tongxinluo+routine vs Danshen compounds+routine</NAME>
<CONT_DATA CI_END="-0.5598050132021744" CI_START="-12.000194986797824" EFFECT_SIZE="-6.279999999999999" ESTIMABLE="YES" MEAN_1="-13.79" MEAN_2="-7.51" ORDER="3296" SD_1="12.37" SD_2="13.38" SE="2.918520458497193" STUDY_ID="STD-Liang-2002" TOTAL_1="60" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="167.5971897484206" CI_END="9.288743248297134" CI_START="7.642715850448244" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="8.46572954937269" ESTIMABLE="YES" I2="97.01665642036988" I2_Q="91.54491400819417" ID="CMP-001.12" NO="12" P_CHI2="-1.5543122344752192E-15" P_Q="7.30328213249809E-6" P_Z="0.0" Q="23.65440164580564" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="13.815920619851005" TOTALS="SUB" TOTAL_1="181" TOTAL_2="182" UNITS="" WEIGHT="300.0" Z="20.160691178422567">
<NAME>NO level</NAME>
<GROUP_LABEL_1>TXL or before</GROUP_LABEL_1>
<GROUP_LABEL_2>Control or after</GROUP_LABEL_2>
<GRAPH_LABEL_1>TXL or before</GRAPH_LABEL_1>
<GRAPH_LABEL_2>control or after</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.6558431084284193E-29" CI_END="9.987318016484396" CI_START="8.2126819835156" DF="1" EFFECT_SIZE="9.099999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.01" NO="1" P_CHI2="0.9999999999999968" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0" Z="20.100653799390177">
<NAME>Change from baseline: tongxinluo capsule</NAME>
<CONT_DATA CI_END="10.13773260335595" CI_START="8.062267396644046" EFFECT_SIZE="9.099999999999998" ESTIMABLE="YES" MEAN_1="28.9" MEAN_2="19.8" ORDER="3297" SD_1="2.1" SD_2="2.0" SE="0.5294651389216606" STUDY_ID="STD-Han-2004a" TOTAL_1="30" TOTAL_2="30" WEIGHT="73.11183367063435"/>
<CONT_DATA CI_END="10.811191864110969" CI_START="7.388808135889033" EFFECT_SIZE="9.100000000000001" ESTIMABLE="YES" MEAN_1="30.78" MEAN_2="21.68" ORDER="3298" SD_1="3.94" SD_2="2.71" SE="0.8730731164493994" STUDY_ID="STD-Jia-1999" TOTAL_1="30" TOTAL_2="30" WEIGHT="26.888166329365646"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="11.23402699884252" CI_END="11.157774970258377" CI_START="4.927835701277434" DF="1" EFFECT_SIZE="8.042805335767905" ESTIMABLE="YES" I2="91.09847252367265" ID="CMP-001.12.02" NO="2" P_CHI2="8.031154573208132E-4" P_Z="4.1794379112843416E-7" STUDIES="2" TAU2="4.606120967741946" TOTAL_1="61" TOTAL_2="61" WEIGHT="100.0" Z="5.0605979006116995">
<NAME>Change from baseline: isosorbide mononitrate</NAME>
<CONT_DATA CI_END="7.573516486230295" CI_START="5.426483513769705" EFFECT_SIZE="6.5" ESTIMABLE="YES" MEAN_1="26.7" MEAN_2="20.2" ORDER="3299" SD_1="2.4" SD_2="1.8" SE="0.5477225575051662" STUDY_ID="STD-Han-2004a" TOTAL_1="30" TOTAL_2="30" WEIGHT="51.48410893811622"/>
<CONT_DATA CI_END="11.198381536619241" CI_START="8.161618463380766" EFFECT_SIZE="9.680000000000003" ESTIMABLE="YES" MEAN_1="32.02" MEAN_2="22.34" ORDER="3300" SD_1="3.68" SD_2="2.25" SE="0.7746986927290694" STUDY_ID="STD-Jia-1999" TOTAL_1="31" TOTAL_2="31" WEIGHT="48.515891061883785"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.779912422531543" CI_END="4.192974955921645" CI_START="-2.0337327161164116" DF="1" EFFECT_SIZE="1.079621119902617" ESTIMABLE="YES" I2="89.77495956204945" ID="CMP-001.12.03" NO="3" P_CHI2="0.001764292882145413" P_Z="0.496720496925647" STUDIES="2" TAU2="4.539201505376344" TOTAL_1="60" TOTAL_2="61" WEIGHT="100.0" Z="0.6796588577492468">
<NAME>Tongxinluo vs Isosorbide mononitrate</NAME>
<CONT_DATA CI_END="3.6656209608767645" CI_START="1.5343790391232348" EFFECT_SIZE="2.5999999999999996" ESTIMABLE="YES" MEAN_1="9.1" MEAN_2="6.5" ORDER="3301" SD_1="2.05" SD_2="2.16" SE="0.5436941542203055" STUDY_ID="STD-Han-2004a" TOTAL_1="30" TOTAL_2="30" WEIGHT="52.18934339316406"/>
<CONT_DATA CI_END="1.1041938198008376" CI_START="-2.2641938198008376" EFFECT_SIZE="-0.5800000000000001" ESTIMABLE="YES" MEAN_1="9.1" MEAN_2="9.68" ORDER="3302" SD_1="3.49" SD_2="3.21" SE="0.859298350931723" STUDY_ID="STD-Jia-1999" TOTAL_1="30" TOTAL_2="31" WEIGHT="47.810656606835934"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>